1	IN THE SUPREME COURT OF THE UNITED STATES
2	x
3	WILLIAM H. SORRELL, ATTORNEY :
4	GENERAL OF VERMONT, ET AL., :
5	Petitioners : No. 10-779
6	v. :
7	IMS HEALTH INC., ET AL. :
8	x
9	Washington, D.C.
10	Tuesday, April 26, 2011
11	
12	The above-entitled matter came on for oral
13	argument before the Supreme Court of the United States
14	at 10:06 a.m.
15	APPEARANCES:
16	BRIDGET C. ASAY, ESQ., Assistant Attorney General,
17	Montpelier, Vermont; on behalf of Petitioners.
18	EDWIN S. KNEEDLER, ESQ., Deputy Solicitor General,
19	Department of Justice, Washington, D.C.; on
20	behalf of the United States, as amicus curiae,
21	supporting Petitioners.
22	THOMAS C. GOLDSTEIN, ESQ., Washington, D.C.; on behalf
23	of Respondents.
24	
25	

1	CONTENTS	
2	ORAL ARGUMENT OF	PAGE
3	BRIDGET C. ASAY, ESQ.	
4	On behalf of the Petitioners	3
5	ORAL ARGUMENT OF	
6	EDWIN S. KNEEDLER, ESQ.	
7	On behalf of the United States, as	
8	amicus curiae, supporting Petitioners	22
9	ORAL ARGUMENT OF	
10	THOMAS C. GOLDSTEIN, ESQ.	
11	On behalf of the Respondents	32
12	REBUTTAL ARGUMENT OF	
13	BRIDGET C. ASAY, ESQ.	
14	On behalf of the Petitioners	64
15		
16		
17		
18		
19		
20		
21		
22		
23		
24		
25		

1 PROCEEDINGS 2 (10:06 a.m.) 3 CHIEF JUSTICE ROBERTS: We will hear 4 argument first this morning -- this morning in Case 10-779, William Sorrell, Attorney General of Vermont, v. 5 IMS Health Incorporated. б 7 Ms. Asay. 8 ORAL ARGUMENT OF BRIDGET C. ASAY 9 ON BEHALF OF THE PETITIONERS MS. ASAY: Mr. Chief Justice, and may it 10 11 please the Court: 12 Under State and Federal law, doctors write prescriptions for their patients to allow them access to 13 14 drugs that the government deems too dangerous for 15 unrestricted sale. Vermont's law allow doctors to 16 decide whether this information that they're compelled to provide to pharmacies may be used in marketing that 17 18 is directed at them. 19 Drug companies would certainly like to have 20 this information for marketing, but they have no First Amendment right to demand it, just as they have no right 21 to demand access to the doctor's tax returns, his 22 patient files, or to their competitors' business 23 24 records. Vermont's law does not regulate the content 25

3

of the marketing pitches and the advertising that drug
 companies provide about their products or their
 competitors' products. It regulates access to this
 information that's created in a highly regulated regime
 of prescription drugs and in the context of the
 doctor-patient relationship.

7 CHIEF JUSTICE ROBERTS: The purpose -- the
8 purpose is to prevent sales representatives from
9 contacting particular physicians, right?

10 MS. ASAY: I disagree, Your Honor. The purpose of the statute is to let doctors decide whether 11 sales representatives will have access to this inside 12 13 information about what they have been prescribing to 14 their patients. And what -- what the record shows is 15 that what drug companies do is track and monitor doctors 16 very closely to watch when they switch drugs, to watch the trends by which they -- doctors prescribe, by 17 18 gender, by age. And all that information is used to 19 target and to direct the marketing projects --20 JUSTICE SCALIA: But they could use it for 21 other purposes, right? 22 MS. ASAY: The pharmaceutical manufacturers? 23 Right. JUSTICE SCALIA: 24 MS. ASAY: Under this statute they may use

25 it for some limited purposes for clinical trials.

4

1 JUSTICE SCALIA: So what the Chief Justice 2 suggested is right, that the purpose is to stop them 3 from using it in order to market their drugs? 4 MS. ASAY: The purpose is to allow doctors to decide whether the --5 б JUSTICE SCALIA: That's right. 7 MS. ASAY: -- the information should be 8 available. 9 JUSTICE SCALIA: Well, that's right, but that -- that is an impediment to their using it for the 10 11 marketing of drugs. You're -- you're placing that 12 impediment on it. Isn't that the obvious purpose of it? I mean, it doesn't necessarily make it bad, but -- but 13 14 let's not quibble over what the purpose is. 15 MS. ASAY: As with any information that 16 the -- that might inform a marketing campaign, not having the information may be -- make their marketing 17 18 less effective or make it different. 19 JUSTICE SCALIA: That's the purpose. That's 20 the purpose of it, to prevent them from using this 21 information to market their drugs. 22 MS. ASAY: Again, Your Honor, the purpose is to allow doctors to make the decision, and doctors may 23 want to allow its use or not allow its use. But the 24 law --25

5

1	JUSTICE SCALIA: But it's only for that use
2	that you interpose the requirement that the doctor
3	consent. For all other uses you don't require the
4	doctor's consent, right?
5	MS. ASAY: The only the consent
б	requirement in this statute goes to the use for
7	marketing and also to the sale by the pharmacy, and that
8	sale may be for other purposes as well, so there
9	JUSTICE GINSBURG: Ms. Asay, are any of the
10	other purposes, like for insurance purposes, cases where
11	the pharmacist is paid for giving out the prescriber
12	information? Here what they call data miners are paying
13	the pharmacists to get this information. In the case of
14	other, others who have access, do any of them also pay
15	the pharmacists?
16	MS. ASAY: Your Honor, there's two sort of
17	answers to that. The first is that, with respect to
18	pharmacies, the record shows here that the only place
19	that the pharmacies disseminate their information is to
20	the data vendors, and that is a commercial sale, and it
21	is primarily intended for the marketing purpose.
22	Insurers do have information about doctors' prescribing
23	practices and patient information. They have that
24	internally from their own claims and their relationships
25	with doctors and patients. So insurers are not do

б

not need to buy the data from pharmacies. They have it
 without purchasing it.

JUSTICE SCALIA: So -- so the data is not private in the sense that the physician who prescribes knows that nobody will know what he is prescribing and how much he prescribes and how often, because there are a lot of people who do know that, right?

8 MS. ASAY: That's correct, Your Honor, there 9 are people who know what the doctor prescribes and what 10 the patient has received.

JUSTICE SCALIA: So the only thing it assures the physician, the physician who prescribes, is that he won't be bothered by drug companies who, on the basis of their knowledge of information which other people have, approach him in order to market their drugs? That's basically all it assures the prescribing physician, right?

MS. ASAY: It assures the prescribing physician that his information about prescribing practices will not be used for marketing without his consent. It's like the difference --

JUSTICE SCALIA: And, and he could achieve the same objective, could he not, by simply refusing to talk to the marketer. When the marketer says, you know, I want to talk to you about a new drug, he says: I

7

1 don't talk to drug manufacturers and marketers. 2 MS. ASAY: He could not achieve the same 3 result, Your Honor. What the record shows is that 4 doctors are particularly concerned about having access to the best information and the most complete 5 information to make decisions for their patients. And б 7 this data, as was discussed by Dr. Granday below, by 8 Kesselheim, by Mr. Erhari, the former sales representative -- they all discussed how the data ends 9 up being used to filter the information that doctors 10 11 receive. So they receive less --12 JUSTICE ALITO: One of the Respondents argues that the statute would permit, does permit, the 13 14 use of this information for what they call a counter-15 detailing effort. Is that correct? 16 MS. ASAY: It is not correct, Your Honor, to the extent that Respondents have suggested that 17 18 Vermont's academic detailing program, which is called 19 the evidence-based education program, uses this data. 20 JUSTICE ALITO: That wasn't really my 21 question. My question was does the statute permit it. If Vermont wanted to do that, the University of Vermont 22 or some other entity wanted to do that, would the 23 statute permit it? 24 25 MS. ASAY: Well, the statute would not

8

1 permit the sale for that purpose, which is a separate 2 provision of the statute, because academic detailing is 3 not an exemption. They would also -- and then the question of whether the information would be available 4 would default back to the pharmacy board rules, which 5 again -б 7 JUSTICE KENNEDY: Could that data be sold to a university for research purposes? The university 8 says: We really want this information to do some 9 10 research. Could the data be sold to the university for 11 that purpose? 12 MS. ASAY: Yes, Your Honor, the statute does permit it to be sold for health care research --13 14 JUSTICE KENNEDY: Could the researcher then 15 have a profile, a data bank, that is very helpful to the 16 general public, and sell that to the general public, to the newspapers and so forth? 17 18 MS. ASAY: We do not believe so, Your Honor, 19 because of the background regulations that govern this 20 information, including Pharmacy Board Rule 20, which we cited at page 4 of our brief, which also places 21 restrictions on disclosure of patient and practitioner 22 23 _ _ 24 JUSTICE KENNEDY: No, no. It's sold to the 25 researcher. The researcher then comes up with a design

9

or database that is very fascinating for a number of 1 reasons. Can that researcher sell it to the New England 2 Journal of Medicine? 3 MS. ASAY: I'm not sure if I understand 4 whether the question is about the data itself or results 5 drawn from the data. But to the extent that the statute б 7 allows the sale of the data for research, the 8 restriction on the other uses would accompany the sale, and --9 10 JUSTICE GINSBURG: Would you clarify --11 JUSTICE KENNEDY: I still am not - I still 12 am not sure. In my hypothetical, what would happen? 13 MS. ASAY: When the -- if the pharmacy sold 14 _ _ 15 JUSTICE KENNEDY: The pharmacy sells to the 16 researcher. 17 MS. ASAY: Right. If that happened --18 JUSTICE KENNEDY: The researcher is at the 19 university. The researcher has a data bank or has some 20 results that are very fascinating. The researcher then 21 wants to sell that to the New England Journal of Medicine. What result under the statute? 22 23 MS. ASAY: The statute would have required the pharmacy to prevent the further dissemination of the 24 25 data except for health care research.

10

1 JUSTICE GINSBURG: You answered my question 2 earlier that they don't sell it to anyone else. That's 3 why I was trying to clarify your answer to Justice Kennedy, because you told me the only sale -- the 4 pharmacists, they sell this to the data miners, they do 5 not sell it to the other people. But now you're б 7 answering Justice Kennedy's question, yes, they sell it 8 to universities. 9 MS. ASAY: I apologize, Your Honor, if I was not clear. As a factual matter, we know absolutely that 10 11 the pharmacies do not sell it to researchers. I had 12 understood this to be a hypothetical, if they did. But as a factual matter, they do not. 13 14 JUSTICE SCALIA: How does it increase the 15 prescribing physician's right of privacy that the data 16 about his prescribing can only be given away but can't be sold? Does that make him feel happier about his 17 18 privacy? 19 MS. ASAY: What it allows the doctor to do 20 is to avoid an intrusive and invasive marketing 21 practice. 22 JUSTICE SCALIA: He can do that by saying: 23 I don't want to talk to you. 24 MS. ASAY: The doctor cannot -- can shut off any communication and any information from the 25

11

pharmaceutical companies by slamming the door on the detailers, but that's not necessarily in the interest of doctors or patients. And what this --

4 JUSTICE SCALIA: That may well be, but then just don't tell me that the purpose is to protect their 5 privacy. Now you're arguing a totally different 6 7 purpose: It makes it easier for the physician to cut 8 off approaches by drug companies that want to sell 9 drugs. If that's the purpose of this statute, it's quite different from protecting his privacy. His 10 11 privacy isn't protected by saying you can't sell it but 12 you can give it away.

13 MS. ASAY: Your Honor, I think the 14 legislature here was using privacy to refer to the 15 autonomy interest that everyone has to some degree in 16 controlling the flow or the use of information about them. This Court recognized in the Reporters Committee 17 18 case in the FOIA context that there was a privacy 19 interest in the aggregation of information on an FBI rap 20 sheet.

JUSTICE SOTOMAYOR: Counsel, that -assuming there's some form of privacy that relates to not being harassed because there's certainly legislative record of doctors or groups of doctors testifying to feeling harassed by detailers, if Thompson requires a

12

1 less restrictive method, why does this have to be an opt-in rather than an opt-out? Because isn't an opt-out 2 3 I call up and say I, don't want you to have this information? So isn't an opt-out less restrictive? 4 5 MS. ASAY: An opt-out would not protect the privacy interests as much because it would assume that 6 7 doctors want to consent. I would like to say that here 8 the statute is --

9 JUSTICE SOTOMAYOR: Well, but, given the restrictions on speech, why is that a bad thing? 10 11 Meaning you don't really intend to tell us that the State couldn't and wouldn't -- just like we got all of 12 13 that advertising relating to the opt-out on telephone 14 solicitations, virtually every American knew they could 15 do it if they chose. Maybe some didn't, but a vast 16 majority did. You can't really say Vermont's incapable of telling doctors in a mailing or in some public 17 18 professional magazine, if you want to opt out, here's 19 the number?

MS. ASAY: Well, in fact, Your Honor, that's exactly what the State does. Every time that the doctors relicense, which is every 2 years, they get a form and they can make a decision one way or the other on the form that they receive. So it's perfectly tailored to allow the doctors to decide and to not

13

1 restrict any marketing between a willing listener and a 2 willing speaker.

3 JUSTICE GINSBURG: There's another --4 there's another purpose that I would like you to comment on, and that is the, the State is interested in 5 promoting the sale of generic drugs and correspondingly б 7 to reduce the sale of brand name drugs. And if that's 8 the purpose, why doesn't that run up against what this 9 Court has said that you can't, you can't lower the 10 decibel level of one speaker so that another speaker, in this case the generics, can be heard better? 11 12 MS. ASAY: The State does have an interest in reducing health care costs here. What's important 13 14 about this statute is the mechanism by which it allows 15 doctors to decide what information and what kind of 16 marketing they want, and it's different because what 17 it's about is access to information in this highly 18 regulated area. It's the difference between a doctor 19 who prescribes a nonprescription drug and a patient who 20 can take that information, walk into the pharmacy with a 21 \$20 bill and leave with their medication, and no one has 22 learned anything about what the doctor prescribed for 23 the patient, about the patient's concerns, or the 24 doctor's concerns.

CHIEF JUSTICE ROBERTS: You want to lower --

14

25

you want to lower your health care costs, not by direct 1 regulation, but by restricting the flow of information 2 3 to the doctors, by, to use a pejorative word, but by 4 censoring what they can hear to make sure they don't have full information, so they will do what you want 5 them to do when it comes to prescribing drugs, because б you can't take, I gather, direct action and tell them, 7 8 you must prescribe generics, right? 9 MS. ASAY: I disagree, Your Honor, for -for two reasons. The statute does not limit any of the 10 information that doctors receive. So the State has not 11 12 in any way intervened in the information that the pharmaceutical manufacturers can provide to the doctors. 13 14 They are free --15 CHIEF JUSTICE ROBERTS: You're restricting 16 their -- you're -- you're making it far more burdensome for the manufacturers to reach their intended audience, 17 18 It's as if I want -- there's a demonstration in right? 19 town, all right? They need a permit to hold the 20 demonstration. They get the permit. I want to hold a 21 counter-demonstration, and you're saying it doesn't make any difference whether I know where their demonstration 22 is going to be or not? 23

24 MS. ASAY: I disagree, Your Honor. The --25 the ability of drug companies to locate the doctors that

15

are interested in their products is -- is not something
 that calls for this data. It's very --

3 JUSTICE KENNEDY: Well, I think maybe you're 4 being -- you were the one that made the argument that the State has an interest in reducing health care costs. 5 I assume that is by selling generics. And the Chief б 7 Justice asked you a question: In effect, aren't you 8 doing this by regulating speech? And you say no, you 9 disagree. I don't understand that answer that you gave 10 to the Chief Justice.

11 MS. ASAY: It's not a restriction on speech 12 because it's a restriction only on the access to the 13 information that the pharmaceutical manufacturers would 14 like to use to inform their advertising, and it's only 15 in play if the doctors have objected to the use. 16 JUSTICE SCALIA: The information necessary for effective speech is what you're saying, right? 17 18 MS. ASAY: Your Honor, it's --19 JUSTICE SCALIA: It only restricts the 20 information necessary for really effective speech? MS. ASAY: No, I disagree. For 21 22 pharmaceutical manufacturers to approach --23 JUSTICE SCALIA: They're looking for it because it -- it identifies those doctors that they 24 25 would like to approach with their information which may

16

1 say, you know, our product is much better than the 2 generic; our quality control is -- you know, whatever. 3 There are arguments on both sides of those things. And 4 you are making it more difficult for them to speak by 5 restricting access to information that would enable 6 their speech to be most effective.

7 MS. ASAY: And -- their speech would be more 8 effective if they had access to patient information, if they had access to their competitors' trade secrets. 9 10 There's certainly other information available that they 11 would like to use in marketing, but is not available to 12 them by law, and it -- it's our position that in the 13 same way they do not have a right to demand access to 14 information about the doctor's prescribing practices 15 without his consent.

If there are no further questions --CHIEF JUSTICE ROBERTS: Well, we'll -- we'll give you -- we seem to have questions. We'll give you additional time for rebuttal, so you don't -- don't worry that we're cutting into that.

But you're making a judgment about how their -- whether or not their speech will be as effective or not. Don't you think they're the ones who are entitled to make that judgment? It doesn't mean that you're right or wrong. It just means that we would

17

1 not rely on your determination that it is -- their 2 speech is just as effective. They're the ones doing the 3 speaking and they think it's not. 4 MS. ASAY: Again, Your Honor, I don't think we disagree that the -- the pharmaceutical manufacturers 5 consider this information useful and helpful in б 7 targeting their marketing campaigns. The issue in this 8 case is whether their right trumps the right of the doctor. 9 10 And if you go back to -- to the source of 11 this information, to the underlying transaction, the 12 doctor prescribing the drug for a patient and the pharmacy dispensing it, the doctor and the pharmacy have 13 14 the same stake in that transaction. And until this 15 point the pharmacy has had complete control over whether 16 the information gets sold into this commercial stream for marketing use. And all the statute does is put the 17 18 doctor on the same -- in the same place as the pharmacy 19 in terms of deciding what further use can be made of the 20 information. 21 JUSTICE ALITO: Can I ask you this question? 22 Do you agree with the Solicitor General's interpretation 23 of the statute? 24 MS. ASAY: Yes, we do, Your Honor.

JUSTICE ALITO: Did you make that argument

25

18

1 below? Is that a change in your position? 2 MS. ASAY: It is not a change in our 3 position. It is not an issue that was pressed below, 4 because of the facts on the ground. There is only one transaction here. There's a sale from the pharmacies to 5 the data vendors for these commercial purposes. б 7 JUSTICE KENNEDY: But isn't this 8 inconsistent with what you told the court of appeals? 9 MS. ASAY: In our court of appeals brief, for example, at page 29 to 30, we describe that sentence 10 11 of the statute as restricting both the sale of the 12 information and the use for marketing. And on page --13 JUSTICE KENNEDY: So you -- you're 14 representing to us that you told the court of appeals 15 the statute should be interpreted as the SG is 16 interpreting it here; that's your representation? 17 MS. ASAY: It is my representation that --18 that we did not say anything contrary to that, Your 19 Honor; and that it really was not pressed below. So I 20 would not say that we, in our briefs below, fully laid out the position as the SG has, but we did not disagree 21 with it, either. 22 23 JUSTICE SCALIA: Well, that's an important position. If you -- if that indeed was the meaning of 24 25 the statute, you should have told the court of appeals,

19

don't you think? Is it enough to say we didn't say no?
 You should have said yes. You should have said this is
 what it means.

4 MS. ASAY: And again, Your Honor, if I could point also to pages 47 to 48 of our -- of our Second 5 Circuit brief, we did frame the issue as whether there 6 7 was a right to buy and sell prescription records. The 8 issue has always been in the case. But again the facts on the ground, there has only been this one transaction, 9 10 and that -- that really was what we were litigating 11 about.

JUSTICE ALITO: Well, the court of appeals on page 22a of the petition, summarizing what it understood you to be arguing, says: "The statute only imposes restrictions on the sale or use of such data for marketing or promoting a prescription drug." That was an inaccurate characterization of your -- the Second Circuit did not understand your argument?

MS. ASAY: Again, Your Honor, I -- I don't think that the argument was really framed clearly below. But we did not --

JUSTICE ALITO: Could you please -- could you please answer yes or no? If you're changing your position, you're changing your position. It seems to me this is an important point, and if the Second Circuit

20

1 based its decision on a misunderstanding of Vermont's 2 interpretation of its own statute, I would think you 3 would at least bring that out in the petition for 4 rehearing. 5 MS. ASAY: I -- I understand, Your Honor. JUSTICE ALITO: And you did not? 6 7 MS. ASAY: We did not. 8 JUSTICE KAGAN: And could you explain how you're going to interpret your statute going forward and 9 apply your statute going forward? 10 MS. ASAY: Yes, Your Honor. We interpret 11 12 the first clause of the statute to be a restriction on sale, except for sale for the exemptions that are set 13 14 forth in the statute. And the other provisions of the 15 statute: The second provision is a restriction on the 16 use for marketing; and the third provision is a restriction that would apply to pharmaceutical 17 18 manufacturers who have obtained the data for permissible 19 purposes and -- and need to abide by the continuing 20 restriction on the use. And the consent provision would 21 apply to each of those parts of the statute. 22 Thank you. 23 CHIEF JUSTICE ROBERTS: We'll afford you 5 24 minutes for rebuttal. 25 Mr. Kneedler.

21

	official Subject to Final Review
1	ORAL ARGUMENT OF EDWIN S. KNEEDLER,
2	ON BEHALF OF THE UNITED STATES,
3	AS AMICUS CURIAE, SUPPORTING the PETITIONERS
4	MR. KNEEDLER: Mr. Chief Justice, and may it
5	please the Court:
6	The Vermont statute protects important
7	interests that the Vermont legislature could recognize
8	in physician autonomy and control over information that
9	concerns them. When a patient brings a prescription to
10	a pharmacy, after that point the patient information is
11	protected under HIPAA and under State law. That leaves
12	two primary actors in that transaction the physician
13	and the pharmacy. Both are professionals, both are
14	subject to regulation under a comprehensive, closed
15	system for the distribution of drugs.
16	Prior to the time this statute was enacted,
17	the pharmacy had complete control over the disposition
18	of that information. What this statute does is put the
19	physician, the prescriber, on an equal footing with
20	respect to the pharmacy with the pharmacy, with
21	respect to the use of the information about that
22	prescriber, but only with respect to the use of the

24 narrowly drawn statute that enables the physician, not 25 the State, enables the physician to determine whether

23

22

information in marketing to that prescriber. It is a

the information that he was required to furnish in connection with the prescribing of a drug will be used in the marketing of products to that -- to that physician.

5 CHIEF JUSTICE ROBERTS: So he's required to 6 provide it, but he would be required to provide it quite 7 apart from the government regulation, right? I mean, 8 the pharmacy needs to know who to make the prescription 9 out to.

10 MR. KNEEDLER: Well, it's because it's a 11 prescription drug. Federal and State law require a 12 prescription for a prescription drug. But if this was not a prescription drug, a person can go into a drug 13 14 store and purchase a nonprescription drug just like any 15 other item in a drug store, not have to furnish the 16 name, not have to furnish any of this information. So the information is furnished because of the requirement 17 of a prescription which is of long standing. 18

19 So this statute is really of a piece with a 20 -- with a number of other types of regulations to 21 protect -- protect privacy, for example, the Driver's 22 Privacy Protection Act, where a person is required to 23 furnish certain information in order to get a driver's 24 license. That statute prohibits the commercial 25 exploitation of that information.

23

1	JUSTICE SCALIA: But it doesn't protect his
2	privacy. I mean, the his name and and the extent
3	of his prescriptions can be given away for a lot of
4	uses. It doesn't protect his privacy.
5	MR. KNEEDLER: It it
6	JUSTICE SCALIA: It protect it enables
7	him to protect himself against drug companies that want
8	to talk to him.
9	MR. KNEEDLER: And that's the term
10	"privacy" is used to embrace that sort of autonomy and
11	control over information. That's that's the way in
12	which we're
13	JUSTICE SCALIA: All right, so long as I
14	know that's what you're talking about. When you say
15	"privacy," you don't mean the prescriber's concern that
16	people will know that he prescribed certain drugs. He
17	doesn't care about that, right.
18	MR. KNEEDLER: Well, he certainly does
19	JUSTICE SCALIA: That is not protected by
20	this law.
21	MR. KNEEDLER: He he certainly he
22	certainly does care about that. And the
23	JUSTICE SCALIA: It's not protected by this
24	law.
25	MR. KNEEDLER: Well, there are other

1 there are other principles that protect it. The --2 the -- the State's pharmacy regulations require pharmacies to maintain the confidentiality --3 4 JUSTICE SCALIA: I'm talking about what this law protects. It does not protect his privacy in that 5 It protects his privacy in the sense that it б sense. 7 enables him to avoid having to say go away when a 8 salesman for the -- for the -- for the drug company comes, right? 9 10 MR. KNEEDLER: Yes, well -- it -- it -- it's 11 a lesser version of that, a less restrictive version of 12 that, because it doesn't put either the pharmaceutical 13 company or the physician in the position of an 14 all-or-nothing situation. 15 What -- what the law allows is the physician 16 to -- to say, you can -- you can come visit me, but I don't want you to use this information that has 17 18 otherwise been kept confidential under pharmacy rules to 19 market to me. That enables the physician to choose to 20 have what the physician may choose -- may see as a more 21 objective presentation. It puts --22 JUSTICE SCALIA: You mean it doesn't even 23 protect his privacy in the sense that it enables him not to have to say go away. It doesn't even protect that. 24 25 They -- he -- he will still have to say that --

25

1	MR. KNEEDLER: If he if he doesn't
2	JUSTICE SCALIA: if the drug company
3	approaches him without having this information.
4	MR. KNEEDLER: If if he doesn't want to
5	talk to the to the detailer at all.
б	JUSTICE SCALIA: All right.
7	MR. KNEEDLER: But what this allows for
8	physicians see value to this, but what this allows for
9	is for the physician to say: I don't want my
10	information to be used by this drug company in a way
11	sort of inside information about my overall prescribing
12	practices. I would I would prefer to have a
13	presentation made to me without the information about
14	me, but information about the drugs that might be
15	JUSTICE ALITO: What about the doctor who
16	didn't want the information distributed to anybody,
17	academic researchers, anybody? Does the law give
18	that give the doctor that option?
19	MR. KNEEDLER: It it does not, but
20	that's that's common in in in confidentiality
21	statutes. For example, HIPAA, which protects the
22	personal information of of persons in the health care
23	system, that information can be used and frankly would
24	have to be used, for example, for paying insurance
25	claims. The insurer needs to know what prescriptions or

1	what other medical services might have been provided.
2	The same thing with respect to insurers
3	controlling their costs, because there are formularies
4	and preferred drug lists. And so, people in that
5	position necessarily have to be able to use prescriber
6	information in order to find out whether whether
7	something was suitably prescribed under the preferred
8	drug list. So, it it's
9	CHIEF JUSTICE ROBERTS: I thought our
10	precedents made indicated that it's problematic for
11	the State to make a determination about what uses
12	information can be to what uses information can be
13	put, particularly when it's an interested party as it is
14	here.
15	MR. KNEEDLER: Well, what the statute does
16	is allow the physician or the prescriber to make that
17	choice. It's information about the prescriber that the
18	prescriber was required to furnish in connection with
19	issuing a prescription.
20	CHIEF JUSTICE ROBERTS: I thought you told
21	me that I thought you told me that this doesn't
22	protect physician privacy to the extent of saying this
23	information can't be used for academic purposes even if
24	you, the physician, don't want it to be used for those
25	purposes?

1	MR. KNEEDLER: Right, and and and
2	again, that that's true in a variety of of
3	CHIEF JUSTICE ROBERTS: So the physician
4	doesn't get to decide for what uses the information
5	MR. KNEEDLER: Not not not altogether,
6	but that doesn't mean that there is no confidentiality
7	interest or no autonomy or control interest, because a
8	physician practicing medicine knows that his patient's
9	insurer is going to
10	CHIEF JUSTICE ROBERTS: What if the statute
11	I'm sorry. What if the statute said this information
12	can be used for any number of purposes, except not for
13	anybody who is going to criticize the State of Vermont?
14	MR. KNEEDLER: No, that would not be that
15	would not be permissible. It would not be germane to
16	CHIEF JUSTICE ROBERTS: This information
17	this information cannot be used for any purposes can
18	be used for any purposes except a purpose that will make
19	things more expensive for the State of Vermont?
20	MR. KNEEDLER: Well, I mean, that's
21	that's a very broad goal. I mean, here here what the
22	State has done is is put the control in the
23	physician, who is a critical player in the in the
24	delivery system. So it's narrowly tailored to the
25	physician's use of the information about him in in

1 connection with how -- how he will be approached. 2 It's also important to recognize that this 3 is very different from the general advertising cases 4 this Court has had under the commercial speech doctrine. This is not public advertising. This I think falls into 5 the camp of Dun and Bradstreet, where you have a -- a б 7 targeted limited business audience, a -- a -- really 8 one-on-one. It's not -- it's not radio or television 9 advertising. It's one-on-one advertising in which the 10 public interest is -- is much more limited, and it's 11 one-on-one with respect to the very person whose 12 information was first furnished by the physician to the pharmacy, so --13 14 JUSTICE KENNEDY: Well, that's because the 15 pharmaceutical company deems this to be the most 16 efficient. What you're saying is that the State can prohibit the most efficient sort of speech, whereas if 17 18 it just had general dissemination which didn't serve any 19 particular purpose, that would be all right. 20 MR. KNEEDLER: But it --JUSTICE KENNEDY: -- but if it becomes --21 22 becomes focused and important and effective, then the State can prohibit it. 23 24 MR. KNEEDLER: It's allowing the other person to that representation visit to decide whether 25

29

1	information about him, not other information; about him
2	will be used in that situation. It's very much like
3	a don't a "do not call" statute or a "do not mail"
4	statute, in which people have the right to say: Do not
5	contact me for commercial information, except this one
б	is more limited. This one says
7	CHIEF JUSTICE ROBERTS: What if you say
8	MR. KNEEDLER: do not use information
9	about me to contact me.
10	CHIEF JUSTICE ROBERTS: Let's say I don't
11	like to be bothered by people knocking on my door by
12	saying, sign this petition. Can I to protect my
13	privacy interests, can I prevent that as a general
14	matter?
15	MR. KNEEDLER: No, but you could post a sign
16	saying "no solicitations," and I think under this
17	Court's cases that that sort of protection
18	JUSTICE SCALIA: Can the State enact a law
19	that, say, petition signers cannot approach somebody
20	unless he has given his prior consent?
21	MR. KNEEDLER: No, but I think the
22	JUSTICE SCALIA: Of course not.
23	MR. KNEEDLER: But I think the State
24	could could enact a law that said if someone posts a
25	sign saying do not do not approach me, do not knock

30

1 on my door for this purpose --

2 JUSTICE SCALIA: Doctors can do that if they
3 don't want to talk to the --

4 MR. KNEEDLER: If they don't want to talk at all. But this -- but this -- this is -- this is 5 addressed to a more limited problem and therefore is б 7 more narrowly tailored, which is that it -- what --8 what -- what the pharmaceutical company can't do without the physician's consent is to -- is to use information 9 10 that was gathered about that very individual to approach 11 him.

12 It puts -- it puts the physician on an equal 13 footing with the pharmacy at the -- at the beginning of 14 the -- of the stream of commerce, it puts the physician 15 on -- on an equal footing with the pharmacy or the 16 pharmaceutical company at the other end by saying: I'm 17 going to keep that information about me to myself if 18 you'll -- if you are approaching me.

JUSTICE GINSBURG: Mr. Kneedler, in most of our commercial speech cases there has been a commodity. Here it's a record maintained by the pharmacist. We think of a pharmacist as selling the brand name or generic name, but whose list is this? Whose record is it? Is it the pharmacist's record the way goods, stock in trade, would be?

31

1	MR. KNEEDLER: May I answer answer the
2	question?
3	CHIEF JUSTICE ROBERTS: Yes.
4	MR. KNEEDLER: It is it is in the
5	possession of the pharmacy. But what the State has done
6	is to legitimately recognize that the physician has a
7	stake in some of the information on that list, and in
8	that respect the list is a is a commodity. The State
9	is regulating its commodity aspect, not its
10	communicative or expressive aspect, in in this
11	statute.
12	CHIEF JUSTICE ROBERTS: Thank you, counsel.
13	Mr. Goldstein.
14	ORAL ARGUMENT OF THOMAS C. GOLDSTEIN
15	ON BEHALF OF THE RESPONDENTS
16	MR. GOLDSTEIN: Mr. Chief Justice, and may
17	it please the Court, good morning:
18	You will want to have available you to the
19	red brief of IMS Health, Incorporated, which in its
20	appendix reproduces the statutes and findings. And the
21	reason we have to look at the statutes and findings in
22	this argument is because the case can't be decided as a
23	matter of absolutes.
24	We know that statutes like HIPAA do protect
25	private information in third parties' hands and they are

1 constitutional. On the other hand, we also know that a governmental restriction on the use of information could 2 3 be used to distort the marketplace of ideas. So the 4 case is going to have to be decided somewhere in the middle. And in order to do that, we're going to have to 5 figure out where in the middle Vermont ended up. б 7 Now, in doing that I want to clarify I think 8 three things in the questioning of the first half hour. They are about what the practice are -- practices are at 9 issue here; what this statute does, actually what's the 10 11 rule; and why is it that Vermont did it. 12 So as to Justice Ginsburg's question, are there other sales, the State gave you the correct answer 13 14 that the pharmacy companies don't sell to researchers, 15 but that's somewhat misleading. They sell to us, and we 16 sell to the researchers, we sell to the government, the intermediaries like IMS Health. That's because we're 17 the aggregator. So it is not correct to say that the 18 19 only sale is for pharmaceutical marketing. 20 Second, on the important question of what 21 this statute --22 JUSTICE GINSBURG: I asked whether there are 23 sales to any other entities. 24 MR. GOLDSTEIN: Yes, and I said the State gave you the accurate answer. But the implication of 25

33

1 the answer I think was not quite correct, because there are sales for purposes other than for marketing. 2 3 JUSTICE KAGAN: But if this was a general 4 sale provision, then that would include those sales that you're talking about? 5 MR. GOLDSTEIN: It would not, because the 6 7 point would then -- and I'll come to the statute in a 8 minute, because all the exemptions -- right? So 9 there's -- there's a debate that Justice Alito focused 10 on about what does the statute mean, and I do want to 11 turn to that in a second. 12 But to jump ahead to your question, Justice Kagan, assume that it's a general sale prohibition. 13 14 Then there are all the exemptions and the exemptions 15 take all of these other uses out from the sale 16 prohibition: for academic research, to go to the government, and for clinical trials, for health care 17 18 research. Those are all exempted from the general sale 19 prohibition. 20 So let's do turn, if you don't mind, to what 21 it is the statute actually does. It is an important 22 point. First, I am going to come to our brief, but I

I'm going to have been reading from page 42 of PhRMA's brief, and this is what -- what the State told the

23

34

just want to read something. For your later reference

Second Circuit, quote: "Data vendors may continue to
 acquire, edit, and sell this information to whomever
 they choose so long as that person does not use the
 information for detailing."

5 In turn, the Second Circuit --

JUSTICE KENNEDY: What was your page again?
MR. GOLDSTEIN: Sorry. That's going to be
from the PhRMA brief, the other red brief at page 42, at
the top of the page.

10 So, to whomever they choose, so long as that 11 person does not use the information for detailing. The Second Circuit said: Okay, you're the State; here's how 12 we understand the statute. The statute only imposed --13 14 quoting again, this is from 22A, it's the language that 15 Justice Alito quoted -- the statute only imposes "restrictions on the sale or use of such data for 16 marketing or promoting a prescription drug." So that's 17 18 what they understood the statute to do.

Now, then the question becomes why did they do it? This was -- Justice Scalia, you tried really hard to get them just to admit, let's just acknowledge what the point is here. And the State tries to deny that the purpose here is to limit the information getting into the hands of the doctor. We don't have to rely on the State's lawyers. The State legislature was

35

1 very helpful here. 2 So if we go to the appendix of the IMS brief 3 now, page 1a, okay. Right at the top, the State says 4 their goal is -- this is finding number 1 at the bottom of it -- containing health care costs. 5 Then in finding number 2 they explain why б 7 they did it: "There is a strong link between pharmaceutical marketing activities, health care 8 spending and the health of Vermonters." 9 10 Then finding number 3: "The goals of 11 marketing programs are often in conflict with the goals 12 of the State." 13 And my favorite, obviously, is number 4: 14 "The marketplace for ideas on medicine safety, the State 15 determined, was operating in conflict with the goals of 16 the State." They didn't like the marketplace of ideas. 17 Now, it is true, we acknowledge, that another thing the State wanted to do was to give the 18 19 doctors some more control. It's in -- it's in -- there 20 is an opt-out option. 21 But can I just take you to how the State 22 explained what it was doing? That's just going to be on page 7. Now, the State's lawyer and the Solicitor 23 General have explained to you that they believe that 24 25 doctors were concerned only with marketing and only with

36

1 marketing to them. That's not true. Finding 29. We 2 have to go all the way to number 29 to get to this goal of the State: "Health care professionals in Vermont" --3 4 I'm on page 7: "Health care professionals in Vermont 5 who write prescriptions for their patients have a reasonable expectation that the information in that б 7 prescription, including their own identity and that of 8 the patient, will not be used for purposes other than 9 the filling and processing of the payment for that 10 prescription."

11 It's not just about pharmaceutical 12 marketing. The doctors say -- we all love this; there's 13 stuff about us in our daily lives that we wish was 14 entirely private. The doctors here said: Hey, it would 15 be great for us if this information, we had complete control over it. Doctors also would love if medical 16 malpractice judgments weren't broadly known. There are 17 18 all kinds of government records they would prefer not to 19 be out into the public sphere.

But then we ask ourselves, all right -- and that's why I asked you to have this brief available -what did the State do? Did the State in fact enact a general privacy provision? Is it like HIPAA or instead is all that the State did here target the use for marketing, while it allows the use of the same data for

37

1 the opposite message by insurers and also by the 2 government?

3 So here's the statute. It appears on page 9 4 of the appendix. I want to start with subsection A because the State helpfully reiterates its goals here. 5 The second half of this paragraph: "The State sought to б 7 ensure costs are contained in the private health care 8 sector, as well as for State purchasers of prescription 9 drugs, through the promotion of less costly drugs and 10 ensuring prescribers received unbiased information." 11 That's what they're trying to do. They're trying to 12 say: We would like the drug companies to have a harder time finding the doctors while the insurance companies 13 14 and the State have an easy time finding the doctors. 15 CHIEF JUSTICE ROBERTS: But there is another interest here besides the State's concern about health 16 care costs, and that is the physician's privacy 17 18 interests. 19 MR. GOLDSTEIN: Yes. 20 CHIEF JUSTICE ROBERTS: You can sell this 21 information to whomever you want, right? 22 MR. GOLDSTEIN: Yes. 23 CHIEF JUSTICE ROBERTS: You could sell to it a journalist who wants to expose physicians in a 24 25 particular area who prescribe a lot of a particular

38

1 medication. 2 MR. GOLDSTEIN: Yes. 3 CHIEF JUSTICE ROBERTS: So the public can 4 discern well, this is the quy who is treating these people; we don't like these people, so we're going to 5 Pickett outside his clinic. 6 7 MR. GOLDSTEIN: Sure. 8 CHIEF JUSTICE ROBERTS: Now, nothing 9 prevents you from doing that, right? 10 MR. GOLDSTEIN: That's correct. 11 CHIEF JUSTICE ROBERTS: Well, don't you 12 think that's protecting physicians' privacy, to prevent 13 that from happening? 14 MR. GOLDSTEIN: Oh, I apologize. We're 15 allowed to do it before and after the statute, is my 16 point. Remember, what the statute does is -- and this was the debate that Justice Alito tried to point us to 17 18 about what the statute actually does and the Second 19 Circuit, what it understood the statute to mean. And I 20 should also say the cert petition didn't say that there 21 was a problem with that. 22 Vermont picked out one thing. It said: 23 Look, when drug companies can find the doctors easily, 24 they can persuade the doctors to use more expensive 25 drugs. We pay a lot for drugs. We would prefer that

39

not happen, so we're going to make it harder. And the State will have its counter-detailing program, it will have its drug utilization review program, and insurers will advocate for less expensive drugs. All the other uses are still permitted.

6 If Vermont were serious about protecting the 7 doctors' privacy, as opposed to kind of a, a right of 8 publicity, a control over information about them, it 9 wouldn't have all these exemptions; it would have a 10 provision that says this is private information.

11 JUSTICE BREYER: All right, suppose --12 suppose that the Federal Trade Commission after a 3-year 13 study of pharmaceutical manufacturing practices, decides 14 -- finds the following. They say: We have found that 15 when drugs are sold to doctors it is very important that 16 the doctor find out what's curable, what the drug does, how much it costs; and by the way, all those things 17 18 apply no matter who the doctor is. Who the doctor is, 19 is irrelevant. And therefore marketing that focuses 20 upon who the doctor is and what his previous practices were is irrelevant and harmful and false; and therefore 21 we find that it is a false and deceptive practice under 22 section 5 of the Federal Trade Commission Act to use the 23 following prior practices of the doctor in selling him 24 25 new drugs, because it's irrelevant and because it's

40

1	false and because it's harmful. And they enact that as
2	a as a rule of the Federal Trade Commission.
3	Does the Constitution of the United States
4	forbid them, having made those findings in detail, from
5	controlling advertising to prevent what they have
6	determined is a false and misleading practice?
7	MR. GOLDSTEIN: I do know I don't know,
8	but I do know the First Amendment applies to the rule.
9	JUSTICE BREYER: Oh, nobody says it doesn't
10	apply. The question
11	MR. GOLDSTEIN: They they do. I've got a
12	couple people
13	JUSTICE BREYER: I'm not interested in what
14	they're saying for the present purposes. I'm
15	interested, surprisingly enough, in what I'm saying.
16	(Laughter.)
17	JUSTICE BREYER: So therefore I would like
18	to know the answer.
19	MR. GOLDSTEIN: Right.
20	JUSTICE BREYER: This is a highly regulated
21	industry.
22	MR. GOLDSTEIN: Yes.
23	JUSTICE BREYER: If the Federal Trade
24	Commission's specialists and experts in false and
25	deceptive advertising concludes that this is a false and

1 deceptive practice, are you going to say that the 2 Constitution of the United States forbids them from 3 doing that? 4 MR. GOLDSTEIN: I am, but I'm also going to say that I don't have to win that argument to win this 5 б case. 7 JUSTICE BREYER: Well -- well, when you say you are, is there any precedent that says they can't 8 regulate false and misleading practice? Of course you 9 10 see where I'm going. 11 MR. GOLDSTEIN: I do. 12 JUSTICE BREYER: If they can, why can't 13 Vermont? 14 MR. GOLDSTEIN: Sure. If it's actually 15 false and misleading. You can't just --16 JUSTICE BREYER: Well, they said it was biased --17 18 MR. GOLDSTEIN: I --19 JUSTICE BREYER: -- and they -- they have 20 made a study of it in the legislature and that's their conclusion. 21 22 MR. GOLDSTEIN: I don't think that the 23 government can say that because speech is so influential 24 it is false and biased. But I will say, Justice Breyer, 25 in my defense that --

42

Official - Subject	t to Final Review
Onicial Dublec	

1	JUSTICE SCALIA: I don't take "biased" to
2	mean false. "Biased" means one-sided.
3	MR. GOLDSTEIN: Yes, that's exactly right.
4	And what we like
5	JUSTICE SCALIA: You state the true facts
6	only on one side and not the other.
7	MR. GOLDSTEIN: Right.
8	JUSTICE SCALIA: This case has not been
9	argued as a case restricting false advertising, has it?
10	MR. GOLDSTEIN: No, it's a case about
11	restricting true advertising.
12	Justice Breyer, can I just make one point
13	really quick? And that is, you dissented in Thompson v.
14	Western States and your dissent in that case says these
15	are drugs, the compounded drugs that have not been
16	approved by the FDA, and I'm very concerned that you're
17	evading the FDA regulatory requirements about truthful
18	advertising.
19	These are the opposite drugs. These are the
20	drugs that all the messages that are being conveyed here
21	have been preapproved by the FDA. This is truthful and
22	accurate speech, and the State only wants one side of
23	the debate to get out.
24	JUSTICE BREYER: That's where I was going.
25	MR. GOLDSTEIN: Okay.

1 JUSTICE BREYER: I chose an example that's 2 beyond your case. 3 MR. GOLDSTEIN: That's why it's called a 4 hypothetical. 5 JUSTICE BREYER: But that's why I wondered how you would respond to that. So -- I thought that was б 7 one that was going to be obviously constitutional, but 8 you're going to stop me there. So -- so what I want to 9 say --10 MR. GOLDSTEIN: Yes. JUSTICE BREYER: -- is how is this 11 different? 12 13 MR. GOLDSTEIN: Sure. 14 JUSTICE BREYER: And I suppose I don't know 15 the extent to which this does or does not promote unbiased information from going to the doctors, and 16 isn't that a matter for the doctors themselves and the 17 18 Vermont legislature rather than this Court to decide? 19 MR. GOLDSTEIN: Sure. A couple of things 20 about that. First, as I said, these are messages that have been cleared by the experts. The FDA has to review 21 all the detailing communications. 22 23 Second, the doctors do get to say: I don't want you to come visit me. They do that all the time. 24 My dad's a doctor; he doesn't visit with detailers. 25

44

Official - Subject to Final Review

1	This is instead a rule about whether you can talk
2	about about someone, not talk to someone.
3	The drug companies and the intermediaries
4	are talking about drug about prescriber practices,
5	and you can decide who you want to try and approach.
6	There's nothing alleged to be false or misleading.
7	Third, the way the First Amendment works in
8	the marketplace of ideas that so upsets Vermont is that
9	both sides get to tell their story, right? The thing
10	that is supposed to be biased here is that the drug
11	companies have too much money. That is not a basis for
12	restricting speech.
13	The way it works is if the message is
14	accurate, as the FDA has determined it to be, the drug
15	companies can go make their pitch. Vermont can come
16	along and make the opposite pitch. Terrific. So can
17	insurance companies.
18	But what you can't do is have a rule that
19	says one side is going to have a much harder time
20	getting to their audience.
21	JUSTICE SOTOMAYOR: Mr. Goldstein, I I
22	understand your argument and I have a difficulty. Today
23	with the Internet and with computers, there's virtually
24	no privacy individuals have. Any transaction you do
25	could be spread across the world instantaneously, and

45

1 for the longest time catalogs would sell your name and 2 address to other catalogers, and if you bought one 3 product from one company, you would get a thousand 4 catalogs from 50 million others.

5 Today the industry is policing that, in part 6 to get the State not to intercede, by giving you an 7 opt-out option. And so, if you're a consumer who 8 doesn't want a million catalogs, the industry is giving 9 you the right to opt out, so they don't sell your 10 address.

11 If there is, as I see, some interest that 12 the State legitimately has in protecting that part of 13 the public who says, I entered into this transaction, I 14 didn't really want you to sell my name, I didn't want 15 you to do other things with it, all I did was this 16 transaction, why can't the State say -- there is a difference in my mind between an opt-in and opt-out? 17 18 Why can't the State say, your desire to enter a 19 transaction in which you're doing just that transaction 20 and not others is something we can protect? 21 MR. GOLDSTEIN: It can. And let me explain 22 why it is that that rule -- and let me typify it for you. There is a pending bill in the Congress called the 23 McCain-Kerry Consumer Protection Act and it does what 24 you're talking about. It says we're not just going to 25

46

1 leave it to the industry; we're going to have a set of 2 governmental rules.

Let me distinguish that bill from what goes on under Act 80. What that says is that if you are a consumer and you engage in a transaction, you have the right to opt out of any unauthorized uses, because it's just between you and the business, right?

8 So there are three differences between that 9 and this. The first is the structure of the statute. 10 That's not what this statute does. This statute says 11 every use of the information is just fine, except this 12 one, this one that allows one speaker who we don't 13 really like to go out and convey its message.

14 The second difference is the public 15 importance of the speech involved. What that consumer information would be used for is to make some random 16 consumer pitch to you or about you. This is information 17 18 about lifesaving medications where the detailer goes in 19 and talks about double blind scientific studies that are 20 responsible for the development of drugs that have 21 caused 40 percent of the increase in the lifespan of the American public. So there's a tremendous difference in 22 23 the public importance.

The third is the fundamentally differentnature of the privacy interest. Unlike your consumer

47

Official - Subject to Final Review

1 transaction over the Internet, this is a doctor. You 2 can call up any doctor's office and find out what their 3 prescribing practice is. It's part of their business. 4 Imagine the following conversation, if you will, and that is, and -- and if you want to look for a 5 place in the common law where this comes from, it would б 7 be section 652D of the Restatement (Second) of Torts, 8 what things are private and what aren't. It asks 9 whether a reasonable person would be outraged. 10 If one doctor were to say to another one, 11 you know what, Dr. Smith told people that three out of 12 four times I prescribe Aciphex for -- as a proton pump 13 inhibitor, would anybody be outraged about that? No. 14 But if you knew that the -- the company that you bought 15 from on the Internet was selling that information or if 16 they were giving away private medical information, you 17 would genuinely be outraged. 18 So, Justice Sotomayor, the reason I started 19 this argument about it has to end up in the middle is we 20 know that statutes like that have to be constitutional.

22 controls over information to really distort speech. So
23 the question is, what happens in this statute? And this
24 statute has a structure that's not intended to protect
25 privacy. It would look totally different.

At the same time, we know that the government can use

21

48

1	JUSTICE SOTOMAYOR: I read in one of the
2	briefs that pharmacies were not permitting either
3	patients and/or doctors to opt out; that if a patient
4	came in and said I don't want my doctor's information
5	sold, or a doctor has called the pharmacy and said, I
б	don't want you to sell my information, the pharmacies
7	are not respecting those limitations.
8	MR. GOLDSTEIN: Well
9	JUSTICE SOTOMAYOR: So why don't I read this
10	statute as simply doing what the consumer statutes are
11	doing, which is giving people some control outside of
12	the limited transaction that they're engaged in?
13	MR. GOLDSTEIN: Sure. A couple of things.
14	Remember, the patients have nothing to do with this.
15	The State doesn't give any control to the patient. That
16	would be true before or after. So we're talking about
17	the doctors.
18	I I did concede, when I read you finding
19	29 at page 7 of the appendix, that this does give a
20	little bit more control to the doctor. I mean, it just
21	does.
22	JUSTICE GINSBURG: May I stop you?
23	MR. GOLDSTEIN: Yes.
24	JUSTICE GINSBURG: You say that this statute
25	doesn't give the patient any control. But the patient

is already taken care of by the Federal law. You can't
 -- I mean, the patient is protected. The question is
 whether the physician should be as well.

MR. GOLDSTEIN: I agree, Justice Ginsburg. Justice Sotomayor in her question to me said, why don't I read this as giving -- she said that they aren't giving patients options about what happens with this prescription information. My only point was this statute doesn't change it.

10 You're quite right that our -- our position is no threat to the protection of private health 11 12 information, which is reasonably regarded as extremely confidential. So, on the question of whether it give 13 14 some greater control, it does. But what -- the thing 15 you have to focus on here is the line that it draws in 16 when it gives greater control is a line that's intended to discriminate against a speaker. 17

18 You have to look, take -- I'll give you an 19 example of this, Cincinnati v. Discovery Network. The 20 City of Cincinnati came to you and said, look, we've 21 eliminated the commercial news racks, and these people who want to sell their commercial stuff should use 22 something other than news racks. We're targeting the 23 blight that comes from commercial news racks. This 24 25 Court said: Look, you can't redefine your interests to

50

1 reflect your statute. You can't --2 JUSTICE BREYER: Could the Federal Power --3 the Federal Energy Regulatory Commission say, we want you to collect certain information about who is using 4 what natural gas and give it to the fire department? 5 It's for the fire department in case of emergency, and б 7 what we don't want to have happen is it's used to stove 8 manufacturers to sell homeowners gas stoves. 9 MR. GOLDSTEIN: Sure. 10 JUSTICE BREYER: They could do that? 11 MR. GOLDSTEIN: Yes. That's LAPD v. United 12 Reporting. 13 JUSTICE BREYER: All right, fine. If they 14 could do that, why can't they do this? 15 MR. GOLDSTEIN: Because the key point in 16 LAPD v. United Reporting is that it's in the hands of 17 the government. Let me -- the fact --18 JUSTICE BREYER: Well, this is 19 information -- see, this is information that starts off 20 being collected because the government requires it to be collected. So it's there for that reason. And the 21 22 government says we want you to get this information, it's done for this purpose, so, you know, other 23 purposes, and we don't want it to be used for commercial 24 advertising purposes. That's what they say they've done 25

51

1 in this statute. 2 MR. GOLDSTEIN: That's what they say. 3 They're just not right. 4 The --5 (Laughter.) MR. GOLDSTEIN: This information -- I would 6 7 direct you to the amicus brief -- you don't have to pull 8 it out right now, but for later. The brief of the 9 National Association of Chain Drugstores, if you just 10 make a reference, on pages 10 to 11 collects the history 11 of how this information has been gathered. And they 12 make the point that the Court did in the first 30 13 minutes, that of course the doctor is going to put his 14 name on the prescription. We have to be able to call 15 the doctor and say: I can't read your handwriting. 16 JUSTICE KENNEDY: Suppose you had a statute in which the pharmacy cannot give the information or 17 18 sell the information to anybody; it must remain with the 19 pharmacy. 20 MR. GOLDSTEIN: Yes. 21 JUSTICE KENNEDY: A copy of the prescription 22 must be given to the State of Vermont. The State of 23 Vermont then has the same restrictions that this statute 24 has. That would be LAPD. 25 MR. GOLDSTEIN: That would be LAPD. Ιf

52

1 the -- it would be almost LAPD. 2 JUSTICE KENNEDY: And what -- and I want to 3 know what your answer would be. If LAPD is correct --4 MR. GOLDSTEIN: Right. 5 JUSTICE KENNEDY: Then what ruling would we have to make in my hypothetical case? 6 MR. GOLDSTEIN: Sure. If it's in the hands 7 8 of the -- so let me just make sure I am on the same page. I am going to answer your question directly. 9 10 The pharmacy can't disclose it directly to 11 anyone else. The government gets a copy of it. That 12 does not make it LAPD. If the pharmacy was governmentowned, that would be LAPD. Now, let me answer your 13 14 hypothetical. Right? LAPD, it was an arrest record, it 15 was in the hands only of the State. The Court said: Look, this is the State's information. Justice 16 Ginsburg's concurrence says: It's like a subsidy, the 17 18 decision whether to give it out or not. 19 Now, in your hypothetical, which is it is in 20 a private hand, but it is banned for any other use --21 that would be a real privacy statute. I think that it 22 would still be unconstitutional, but it would be much 23 closer. 24 The reason it might be unconstitutional is twofold. First, that the privacy interest in it I think 25

53

Official - Subject to Final Review

1 is not very significant, because it's how the doctor 2 runs his or her business, and second it would still allow the discrimination. If you were convinced in your 3 4 hypothetical that what Vermont was trying to do is what it said it was doing here in its findings, and that is, 5 to make it harder for the drug companies to reach the б 7 audience and make it easier for the insurance company 8 and the government to reach their audience, Greater New 9 Orleans Broadcasting, which involves a ban on private 10 casino speech but not tribal and governmental speech, 11 says discriminating against speakers like that is very 12 troubling. So that's I think how your hypothetical --13 JUSTICE SOTOMAYOR: So what you're saying I 14 think to Justice Kennedy is answering my earlier 15 question by saying the State cannot constitutionally stop the spread of information. So if the State said to 16 the pharmacy, all you can do is fill the prescription, 17 18 that's what doctors think pharmacies are doing, and 19 that's all you can do, you're saying that's 20 unconstitutional? 21 MR. GOLDSTEIN: I am saying that that's 22 unconstitutional. I am also saying that the reason is very specific to this kind of information, that is that 23 it would allow speaker discrimination, and I am also 24 25 saying most emphatically that is not this case. That

54

1 would be a much closer case. It would look much more 2 like a real privacy statute. 3 What I would take from the hypothetical is 4 not the lesson we should lose -- and you should never take that lesson --5 6 (Laughter.) 7 MR. GOLDSTEIN: -- but the -- but instead 8 the lesson that that's what's so different about this statute. This statute, as in all the language guoted 9 earlier, says Katie bar the door, do whatever you want 10 to do with this stuff, just don't do something we 11 12 disagree with when it comes to the message. 13 JUSTICE SOTOMAYOR: So you're really -- you 14 are really hinging your argument on the discrimination 15 aspect --16 MR. GOLDSTEIN: I am --17 JUSTICE SOTOMAYOR: -- that -- that drug companies or detailers are being treated differently 18 19 than any other user of this information? 20 MR. GOLDSTEIN: That is a principal part of 21 our argument. I did say before in describing the 22 Kerry-McCain bill, that there were three things, not just the discrimination, but the greater public interest 23 24 of the -- the detailer speech and the lower privacy 25 interest, so I wouldn't throw those out.

55

1	Now can I just preempt an argument that my
2	friend from the Vermont State of Vermont is going to
3	say in her rebuttal? And that, is she's going to come
4	and say that, look, the insurance companies are actually
5	paying for the drugs. All their this exception is
б	not one that's about advocacy, and I just want to make
7	sure we all know ahead of time because I don't get a
8	surrebuttal, that that's not accurate.
9	So if if you still have the IMS brief
10	with you at page 53 this time, so at page 53 the first
11	paragraph is about the State's own use of this
12	information for a variety of purposes. There is the
13	reply brief for the State introduces a debate about
14	today whether they are using the NPI data for
15	counter-detailing. There is no dispute that they use it
16	for other State programs, like the drug utilization
17	program that's the quotes in the first paragraph.
18	But the better paragraph is going to be it's the
19	second paragraph, it starts, the State "the statute's
20	parallel formulary compliance exemption." And this
21	paragraph talks about advocacy by the insurance
22	companies. So it's not just that the drug insurance
23	company says to the doctor, I'll pay for \$5 for this
24	drug, but the insurance companies take PI data under the
25	exemption in the statute, go to doctors and say we

really think this cheaper drug would be better. That is
 straight-out speaker discrimination.

3 So we quote Kolassa: "Insurance companies 4 are using physician-identifiable information to call physicians to try to get them to comply with 5 formularies, to try to get them to change their б 7 prescribing in a way that may or may not be in the 8 patient's best interests. In just" -- this is a further quote -- "In just the last couple of years there has 9 10 been an amazing increase in the amount of information 11 provided by payers, insurers that will send scientific 12 documents to physicians" -- I've rolled over to page 53 -- "will call when physicians are prescribing too 13 14 much or too little of a product and provide them with 15 information." It goes on and on -- "virtually several times a day." 16

17 So that is the message that I would take away from the argument, and that is we are emphatically 18 19 in favor of the constitutionality of HIPAA, of the 20 McCain-Kerry bill, the things that concerned you. You have to decide this case in the middle about what 21 Vermont actually did, and it was unbelievably candid 22 about what it was trying to do. It said the marketplace 23 24 of ideas doesn't work for us, and so it designed a 25 statute -- and you can decide this case very narrowly on

57

Official - Subject to Final Review

1	the ground that what Vermont did is it went too far is
2	in just saying we're not actually trying to protect
3	privacy; what we're trying to do is give the doctors
4	control when it suits our own best interests.
5	I do want to preempt one other last
6	argument, and that is the suggestion that this isn't
7	paternalistic at all. Right? We just let the doctors
8	decide. But the State's goal, what the State is trying
9	to do, is paternalistic. The reason the State picked
10	this one exemption, the reason it picked between these
11	speakers, is because it doesn't want this message to get
12	to the doctors. And if you can keep
13	JUSTICE BREYER: It used to be true there
14	was something called a regulated industry.
15	MR. GOLDSTEIN: Yes.
16	JUSTICE BREYER: And selling was within
17	activity among many.
18	MR. GOLDSTEIN: Sure.
19	JUSTICE BREYER: And there were lots of
20	regulations that could be imposed upon selling.
21	MR. GOLDSTEIN: Sure, right.
22	JUSTICE BREYER: Are you saying that all
23	those should be reexamined?
24	MR. GOLDSTEIN: I I thankfully am not.
25	Here are the here are the cases. This was the

58

1 argument that was made and rejected in Virginia Board of 2 Pharmacy which was about a pharmacy rule. They said 3 that it would be unprofessional. Then the Solicitor 4 General in the person of Mr. Kneedler came you to in 5 Thompson v. Western States and said we need to stop this compounded drug marketing because this is heavily б 7 regulated; this is a closed market, and the Court said, 8 I'm sorry, no. The nature of a marketplace of ideas is 9 you get to say your piece and the other side gets to say 10 their piece. The FDA heavily regulates this area, the 11 information is perfectly accurate and it's incredibly 12 valuable.

13 CHIEF JUSTICE ROBERTS: You would have no 14 objection I take it, if there were not the academic 15 exception and if the State didn't -- didn't push its own 16 contrary program?

17 MR. GOLDSTEIN: We would have much less of 18 an objection, and that's no accident. Let me just say 19 this is not a flaw in the drafting. The State really 20 wanted to push its counter message, and thankfully so. 21 This government has a real interest here. Insurers have a real interest here, but so does the other side of the 22 23 debate, and what the State doesn't get to do is just 24 pick sides and prevent the debate from happening. 25

CHIEF JUSTICE ROBERTS: How would -- if you

59

Official - Subject to Final Review

1 were truly concerned about physician privacy --2 MR. GOLDSTEIN: Yes. Yes. 3 CHIEF JUSTICE ROBERTS: You didn't want people to know that this physician prescribed this drug 4 more often because it tells you a lot about his 5 practice -б 7 MR. GOLDSTEIN: Sure. Sure. 8 CHIEF JUSTICE ROBERTS: -- that he may not 9 want known, how would you -- how would you write this 10 statute? 11 MR. GOLDSTEIN: You would take Justice 12 Kennedy's hypothetical, and I don't think the Court has 13 to confront whether such a statute would be 14 constitutional because it would be very different. 15 CHIEF JUSTICE ROBERTS: Would you remind me 16 what Justice Kennedy said? 17 (Laughter.) 18 MR. GOLDSTEIN: Sure. He said the rule is 19 the pharmacy can't give it to anybody. 20 CHIEF JUSTICE ROBERTS: Okay. Who's --21 JUSTICE KAGAN: How about the pharmacy can't 22 sell it to anybody? 23 MR. GOLDSTEIN: I don't -- I don't understand why that protects privacy. That protects 24 25 against commercialization, but I don't think the

60

1 government has nearly as much interest in 2 commercialization as it does in actual privacy. Section 652D of the restatement of torts doesn't talk about the 3 4 outrage of being able to use -- we have a capitalist economy, and we sell newspapers and books and that sort 5 of thing. Commercialization isn't a bad thing. It's a б 7 question of whether privacy is genuinely protected. 8 JUSTICE SOTOMAYOR: Could you do it --9 JUSTICE KENNEDY: It's not exactly not this case but just in the abstract, do we have a rule that if 10 there are two statutes, A, the statute is passed for a 11 12 bad purpose, B, the statute is not passed for a bad 13 purpose, if the statute is otherwise the same, are they 14 both unconstitutional or just one and why? And what 15 case do I look to other than maybe Church of Lukumi? 16 MR. GOLDSTEIN: You look to -- yes, we win -- Thompson v. Western States. Remember what the 17 18 government's argument there was: If you allow the 19 marketing of compounded drugs that are not FDA approved 20 you will evade the very important FDA regulatory 21 program. That was a perfectly important rationale, and 22 the Court said but it also has the purpose of keeping information out of the hands of doctors. 23 It's 24 unconstitutional. 25 I'll give you another example. Grosjean,

61

1 Minneapolis Star and -- Raglan -- those are cases about 2 taxing the instruments of communication. So a tax on 3 newsprint, a tax on ink; and the Court said we're not 4 worried about your bad motive, you have a very important rationale in trying to raise revenue, that's a perfectly 5 valid purpose; but what you're also doing is you're б 7 picking out the press and you're making it harder to 8 speak; it's unconstitutional.

9 CHIEF JUSTICE ROBERTS: This -- this is, Mr. Kneedler explained this is the government's information. 10 11 Why can't -- you wouldn't have to have it if it weren't 12 prescription. It was the fact that it has to be prescribed that requires this information. The 13 14 government frequently controls the use to which 15 information can be put. It makes me file a tax return, 16 and it doesn't allow, you know, dissemination of that. It restricts it. 17

18 MR. GOLDSTEIN: Right.

19 CHIEF JUSTICE ROBERTS: And presumably it 20 could say that if an accountant prepares my tax return, 21 that accountant can't sell it, either.

22 MR. GOLDSTEIN: Right.

23 CHIEF JUSTICE ROBERTS: How is this any 24 different?

25 MR. GOLDSTEIN: Oh, okay. Two pieces to the

62

puzzle. The first is why can't I demand it from the IRS? Okay? And second is going to be why can't the accountant give it away? The first one is LAPD, and it's the same true -- the same thing is true of campaign finance reports. The government has plenary authority; when you give information to the government, what the government then does with the information.

8 The important lesson to be derived from LAPD 9 is that nine members of the Court seemingly agreed --10 and I defended the statute in that case -- nine members 11 of the court in that case agreed that if this had been 12 private reports rather than the government's reports, 13 then the statute would have been unconstitutional.

14 The reason your tax preparer can't give it 15 away, the reason I can't give away attorney-client 16 secrets, the reason that the government is going to be able to tell Internet companies that they can't give 17 18 await the consumer information is that it's really 19 private. But what if, instead, the government had a 20 rule that says tax preparers can't give out tax 21 information when it will encourage people to protest against their taxes? But if it will encourage people to 22 comply with their taxes, it's perfectly fine. You can't 23 24 draw lines that are intended to discriminate against 25 speakers. That's the main principle of our case.

63

1	Thank you very much.
2	CHIEF JUSTICE ROBERTS: Thank you, counsel.
3	Ms. Asay, you have five minutes.
4	REBUTTAL ARGUMENT OF BRIDGET C. ASAY
5	ON BEHALF OF THE PETITIONERS
6	MS. ASAY: I would like to begin with the
7	point that my friend was making about the use of the
8	information by insurance companies. Insurers are not
9	similarly situated to pharmaceutical manufacturers.
10	Insurers receive information directly from doctors and
11	parents in the ordinary course of their business and
12	they use it as part of providing and paying for care to
13	patients.
14	And when my friend described the fact that
15	insurers do that with doctors' information as speaker
16	discrimination, I would like to point out that the
17	not only the record but the examples, for example, that
18	PhRMA points to on page 126 their brief show that
19	insurers have patient information for that purpose as
20	well. HIPAA allows those uses of both patient and
21	prescriber information to manage benefits.
22	So, to argue that pharmaceutical
23	manufacturers are being discriminated against if they
24	don't have access to the same health care information
25	that we provide to our insurance companies would

1 would begin to raise serious questions about a statute 2 like HIPAA. And that -- that just highlights that in 3 this area of -- of private information and information 4 control that many of these statutes are structured in such a way that there are expected and intended and 5 permissible uses of information, and other uses for б 7 which people are allowed to have control over the 8 further use of their information. And here we're talking about the control allotted to doctors. 9

10 We place an enormous amount of trust in 11 doctors to make the right treatment decisions for their 12 Part of their ability to make that, those patients. 13 decisions depends on the information that they receive. 14 And what doctors have said to the Vermont legislature 15 and to the Court in this case is that many of them find 16 this practice objectionable and that it is not helpful to them or to their patients to have their information 17 18 monitored for this marketing purpose. And all that they 19 have asked for is the right to object. And I would like 20 to --

21 CHIEF JUSTICE ROBERTS: Ms. Asay, I want to 22 give you the chance to respond to a point that was 23 highlighted by your friend, which is the fourth 24 legislative finding, which does seem to say that the 25 State is doing this because it doesn't like an imbalance

65

1 in the marketplace of ideas.

2 MS. ASAY: Thank you, Your Honor. 3 The findings, first of all, have to be taken 4 as they were adopted, which was in support of not this statute even as it was written, but as a much larger 5 bill that contained many sections, including a provision б 7 that created the evidence based education program which 8 is a -- a clinical -- a -- a program to provide voluntary education to doctors, and to the statute as it 9 used to be written, which -- which not only had this 10 provision for the doctors' choice and the use of the 11 12 information, but also mandated that pharmaceutical detailers provide information affirmatively as part of 13 14 the marketing process. 15 CHIEF JUSTICE ROBERTS: Do we have -- were 16 there -- were there findings with respect to the statute 17 as enacted? 18 MS. ASAY: There are no findings that 19 accompany the amendment that resulted in this statute. 20 And to -- to return to, I think Justice 21 Kennedy's point from earlier, the statute, I think, has to stand or fall on the restriction that it -- that it 22 allows for doctors. The Court, for example, in O'Brien 23 discussed the fact that striking down a statute because 24 25

the court disagreed with the record would -- would

66

simply mean that the legislature could adopt the same
 statute again on a different record.

We would say here that what -- what's -- the question before the Court really is, may doctors have this opportunity to control the use of their information about -- their nonpublic information about their prescribing practices as a marketing tool or not, and that -- that -- that should be the -- the focus of the Court's inquiry.

I would also like to just return to the point that -- that I believe I was making earlier that this statute is so different from the cases in which the Court has considered restrictions on the direct commercial advertising and the provision of information to the public.

16 This is an entirely nonpublic commercial transmission of data. It -- it starts with a private 17 18 commercial transaction, it's a private commercial 19 exchange between the data vendors and the pharmacies. 20 It's used in a way that it is never disclosed publicly, 21 never included in the advertising message. There's no restriction here on the information that's provided to 22 doctors. The truthful information that the FDA permits 23 to be provided about prescription drugs. And there's no 24 25 restriction on any exchange between a willing listener

67

1 and a willing speaker.

2 I believe my friend suggested that -- that anyone could call a doctor's office and find out by 3 asking what the doctor prescribed. Pharmaceutical 4 5 manufacturers can do that as well. And if the doctor volunteers that information, there can be that exchange б of information. The statute does not restrict it. 7 CHIEF JUSTICE ROBERTS: I take it there's --8 9 there's -- it's against the law for a physician to say I 10 want you to fill this prescription in a particular 11 place, a particular pharmacy because I know that 12 pharmacy doesn't sell the information. They can't do 13 that, can they? 14 MS. ASAY: I don't believe they can, Your 15 Honor. 16 CHIEF JUSTICE ROBERTS: Thank you, counsel. Counsel. The case is submitted. 17 18 (Whereupon, at 11:14 a.m., the case in the 19 above-entitled matter was submitted.) 20 21 22 23 24 25

Α	adopted 66:4	altogether 28:5	approaching	55:15
abide 21:19	advertising 4:1	amazing 57:10	31:18	Assistant 1:16
ability 15:25	13:13 16:14	amendment 3:21	approved43:16	Association 52:9
65:12	29:3,5,9,9 41:5	41:8 45:7 66:19	61:19	assume 13:6
able 27:5 52:14	41:25 43:9,11	American 13:14	April 1:10	16:6 34:13
61:4 63:17	43:18 51:25	47:22	area 14:18 38:25	assuming 12:22
above-entitled	67:14,21	amicus 1:20 2:8	59:10 65:3	assures 7:12,16
1:12 68:19	advocacy 56:6	22:3 52:7	argue 64:22	7:18
absolutely 11:10	56:21	amount 57:10	argued43:9	Attorney 1:3,16
absolutes 32:23	advocate 40:4	65:10	argues 8:13	3:5
abstract 61:10	affirmatively	and/or 49:3	arguing 12:6	attorney-client
academic 8:18	66:13	answer 11:3 16:9	20:14	63:15
9:2 26:17 27:23	afford 21:23	20:23 32:1,1	argument 1:13	audience 15:17
34:16 59:14	age 4:18	33:13,25 34:1	2:2,5,9,12 3:4,8	29:7 45:20 54:7
access 3:13,22	aggregation	41:18 53:3,9,13	16:4 18:25	54:8
4:3,12 6:14 8:4	12:19	answered 11:1	20:18,20 22:1	authority 63:5
14:17 16:12	aggregator	answering 11:7	32:14,22 42:5	autonomy 12:15
17:5,8,9,13	33:18	54:14	45:22 48:19	22:8 24:10 28:7
64:24	agree 18:22 50:4	answers 6:17	55:14,21 56:1	available 5:8 9:4
accident 59:18	agreed 63:9,11	anybody 26:16	57:18 58:6 59:1	17:10,11 32:18
accompany 10:8	ahead 34:12 56:7	26:17 28:13	61:18 64:4	37:21
66:19	AL 1:4,7	48:13 52:18	arguments 17:3	avoid 11:20 25:7
accountant 62:20	Alito 8:12,20	60:19,22	arrest 53:14	await 63:18
62:21 63:3	18:21,25 20:12	apart 23:7	Asay 1:16 2:3,13	a.m 1:14 3:2
	20:22 21:6	apologize 11:9	3:7,8,10 4:10	68:18
accurate 33:25 43:22 45:14	26:15 34:9	39:14	4:22,24 5:4,7	
	35:15 39:17	appeals 19:8,9	5:15,22 6:5,9	B
56:8 59:11	alleged 45:6	19:14,25 20:12	6:16 7:8,18 8:2	B 61:12
achieve 7:22 8:2	allotted 65:9	APPEARANC	8:16,25 9:12,18	back 9:5 18:10
Aciphex 48:12	allow 3:13,15 5:4	1:15	10:4,13,17,23	background 9:19
acknowledge	5:23,24,24	appears 38:3	11:9,19,24	bad 5:13 13:10
35:21 36:17	13:25 27:16	appendix 32:20	12:13 13:5,20	61:6,12,12 62:4
acquire 35:2	54:3,24 61:18	36:2 38:4 49:19	14:12 15:9,24	ban 54:9
Act 23:22 40:23	62:16		16:11,18,21	bank 9:15 10:19
46:24 47:4	allowed 39:15	applies 41:8		banned 53:20
action 15:7		apply 21:10,17	17:7 18:4,24	bar 55:10
activities 36:8	65:7	21:21 40:18	19:2,9,17 20:4	based 21:1 66:7
activity 58:17	allowing 29:24	41:10	20:19 21:5,7,11	basically 7:16
actors 22:12	allows 10:7 11:19	approach 7:15	64:3,4,6 65:21	basis 7:14 45:11
actual 61:2	14:14 25:15	16:22,25 30:19	66:2,18 68:14	beginning 31:13
additional 17:19	26:7,8 37:25	30:25 31:10	asked 16:7 33:22	behalf 1:17,20
address 46:2,10	47:12 64:20	45:5	37:21 65:19	1:22 2:4,7,11
addressed 31:6	66:23	approached 29:1	asking 68:4	2:14 3:9 22:2
admit 35:21	all-or-nothing	approaches 12:8	asks 48:8	2:14 3:9 22:2 32:15 64:5
adopt 67:1	25:14	26:3	aspect 32:9,10	1 1/1 1/4 1

	1	1	1	1
36:24 67:11	brings 22:9	68:17,18	Church 61:15	40:12,23 41:2
68:2,14	broad 28:21	cases 6:10 29:3	Cincinnati 50:19	51:3
benefits 64:21	Broadcasting	30:17 31:20	50:20	Commission's
best 8:5 57:8	54:9	58:25 62:1	Circuit 20:6,18	41:24
58:4	broadly 37:17	67:12	20:25 35:1,5,12	Committee
better 14:11 17:1	burdensome	casino 54:10	39:19	12:17
56:18 57:1	15:16	catalogers 46:2	cited 9:21	commodity 31:20
beyond 44:2	business 3:23	catalogs 46:1,4,8	City 50:20	32:8,9
biased 42:17,24	29:7 47:7 48:3	caused 47:21	claims 6:24	common 26:20
43:1,2 45:10	54:2 64:11	censoring 15:4	26:25	48:6
bill 14:21 46:23	buy 7:1 20:7	cert 39:20	clarify 10:10	communication
47:3 55:22		certain 23:23	11:3 33:7	11:25 62:2
57:20 66:6	<u> </u>	24:16 51:4	clause 21:12	communications
bit 49:20	C 1:16,22 2:1,3	certainly 3:19	clear 11:10	44:22
blight 50:24	2:10,13 3:1,8	12:23 17:10	cleared44:21	communicative
blind 47:19	32:14 64:4	24:18,21,22	clearly 20:20	32:10
board 9:5,20	call 6:12 8:14	Chain 52:9	clinic 39:6	companies 3:19
59:1	13:3 30:3 48:2	chance 65:22	clinical 4:25	4:2,15 7:13
books 61:5	52:14 57:4,13	change 19:1,2	34:17 66:8	12:1,8 15:25
bothered 7:13	68:3	50:9 57:6	closed 22:14	24:7 33:14
30:11	called 8:18 44:3	changing 20:23	59:7	38:12,13 39:23
bottom 36:4	46:23 49:5	20:24	closely 4:16	45:3,11,15,17
bought 46:2	58:14	characterization	closer 53:23 55:1	54:6 55:18 56:4
48:14	calls 16:2	20:17	collect 51:4	56:22,24 57:3
Bradstreet 29:6	camp 29:6	cheaper 57:1	collected 51:20	63:17 64:8,25
brand 14:7 31:22	campaign 5:16	Chief 3:3,10 4:7	51:21	company 25:8,13
Brever 40:11	63:4	5:1 14:25 15:15	collects 52:10	26:2,10 29:15
41:9,13,17,20	campaigns 18:7	16:6,10 17:17	come 25:16 34:7	31:8,16 46:3
41:23 42:7,12	candid 57:22	21:23 22:4 23:5	34:22 44:24	48:14 54:7
42:16,19,24	capitalist 61:4	27:9,20 28:3,10	45:15 56:3	56:23
43:12,24 44:1,5	care 9:13 10:25	28:16 30:7,10	comes 9:25 15:6	compelled 3:16
44:11,14 51:2	14:13 15:1 16:5	32:3,12,16	25:9 48:6 50:24	competitors 3:23
51:10,13,18	24:17,22 26:22	38:15,20,23	55:12	4:3 17:9
58:13,16,19,22	34:17 36:5,8	39:3,8,11 59:13	comment 14:4	complete 8:5
BRIDGET 1:16	37:3,4 38:7,17	59:25 60:3,8,15	commerce 31:14	18:15 22:17
2:3,13 3:8 64:4	50:1 64:12,24	60:20 62:9,19	commercial 6:20	37:15
brief 9:21 19:9	case 3:4 6:13	62:23 64:2	18:16 19:6	compliance
20:6 32:19	12:18 14:11	65:21 66:15	23:24 29:4 30:5	56:20
34:22,25 35:8,8	18:8 20:8 32:22	68:8,16	31:20 50:21,22	comply 57:5
36:2 37:21 52:7	33:4 42:6 43:8	choice 27:17	50:24 51:24	63:23
52:8 56:9,13	43:9,10,14 44:2	66:11	67:14,16,18,18	compounded
64:18	51:6 53:6 54:25	choose 25:19,20	commercializa	43:15 59:6
briefs 19:20 49:2	55:1 57:21,25	35:3,10	60:25 61:2,6	61:19
bring 21:3	61:10,15 63:10	chose 13:15 44:1	Commission	comprehensive
×1119 21.3	63:11,25 65:15		~~~~	
		l	l	l

22:14	contained 38:7	40:2 56:15	debate 34:9	detailer 26:5
computers 45:23	66:6	couple 41:12	39:17 43:23	47:18 55:24
concede 49:18	containing 36:5	44:19 49:13	56:13 59:23,24	detailers 12:2,25
concern 24:15	content 3:25	57:9	deceptive 40:22	44:25 55:18
38:16	context 4:5 12:18	course 30:22	41:25 42:1	66:13
concerned 8:4	continue 35:1	42:9 52:13	decibel 14:10	detailing 8:15,18
36:25 43:16	continuing 21:19	64:11	decide 3:16 4:11	9:2 35:4,11
57:20 60:1	contrary 19:18	court 1:1,13 3:11	5:5 13:25 14:15	44:22
concerns 14:23	59:16	12:17 14:9 19:8	28:4 29:25	determination
14:24 22:9	control 17:2	19:9,14,25	44:18 45:5	18:1 27:11
concludes 41:25	18:15 22:8,17	20:12 22:5 29:4	57:21,25 58:8	determine 22:25
conclusion 42:21	24:11 28:7,22	32:17 44:18	decided 32:22	determined
concurrence	36:19 37:16	50:25 52:12	33:4	36:15 41:6
53:17	40:8 49:11,15	53:15 59:7	decides 40:13	45:14
confidential	49:20,25 50:14	60:12 61:22	deciding 18:19	development
25:18 50:13	50:16 58:4 65:4	62:3 63:9,11	decision 5:23	47:20
confidentiality	65:7,9 67:5	65:15 66:23,25	13:23 21:1	difference 7:21
25:3 26:20 28:6	controlling 12:16	67:4,13	53:18	14:18 15:22
conflict 36:11,15	27:3 41:5	Court's 30:17	decisions 8:6	46:17 47:14,22
confront 60:13	controls 48:22	67:9	65:11,13	differences 47:8
Congress 46:23	62:14	created 4:4 66:7	deems 3:14	different 5:18
connection 23:2	conversation	critical 28:23	29:15	12:6,10 14:16
27:18 29:1	48:4	criticize 28:13	default 9:5	29:3 44:12
consent 6:3,4,5	convey 47:13	curable 40:16	defended 63:10	47:24 48:25
7:21 13:7 17:15	conveyed 43:20	curiae 1:20 2:8	defense 42:25	55:8 60:14
21:20 30:20	convinced 54:3	22:3	degree 12:15	62:24 67:2,12
31:9	copy 52:21 53:11	cut 12:7	delivery 28:24	differently 55:18
consider 18:6	correct 7:8 8:15	cutting 17:20	demand 3:21,22	difficult 17:4
considered 67:13	8:16 33:13,18	D	17:13 63:1	difficulty 45:22
Constitution	34:1 39:10 53:3		demonstration	direct 4:19 15:1
41:3 42:2	correspondingly	D 3:1	15:18,20,22	15:7 52:7 67:13
constitutional	14:6	dad's 44:25	deny 35:22	directed 3:18
33:1 44:7 48:20	costly 38:9	daily 37:13	department 1:19	directly 53:9,10
60:14	costs 14:13 15:1	dangerous 3:14	51:5,6	64:10
constitutionality	16:5 27:3 36:5	data 6:12,20 7:1	depends 65:13	disagree 4:10
57:19	38:7,17 40:17	7:3 8:7,9,19 9:7	Deputy 1:18	15:9,24 16:9,21
constitutionally	counsel 12:21	9:10,15 10:5,6	derived 63:8	18:5 19:21
54:15	32:12 64:2	10:7,19,25 11:5 11:15 16:2 19:6	describe 19:10	55:12
consumer 46:7	68:16,17	20:15 21:18	described 64:14	disagreed 66:25
46:24 47:5,15	counter 8:14	35:1,16 37:25	describing 55:21	discern 39:4
47:17,25 49:10	59:20	56:14,24 67:17	design 9:25	disclose 53:10
63:18	counter-demo	67:19	designed 57:24	disclosed 67:20
contact 30:5,9	15:21	database 10:1	desire 46:18	disclosure 9:22
contacting 4:9	counter-detaili	day 57:16	detail 41:4	Discovery 50:19
		uay 57.10		
L				

[
discriminate	16:15,24 31:2	45:3,4,10,14	emergency 51:6	61:25 64:17
50:17 63:24	36:19,25 37:12	54:6 55:17	emphatically	66:23
discriminated	37:14,16 38:13	56:16,22,24	54:25 57:18	examples 64:17
64:23	38:14 39:23,24	57:1 59:6 60:4	enable 17:5	exception 56:5
discriminating	40:7,15 44:16	drugs 3:14 4:5,16	enables 22:24,25	59:15
54:11	44:17,23 49:3	5:3,11,21 7:16	24:6 25:7,19,23	exchange 67:19
discrimination	49:17 54:18	12:9 14:6,7	enact 30:18,24	67:25 68:6
54:3,24 55:14	56:25 58:3,7,12	15:6 22:15	37:22 41:1	exempted 34:18
55:23 57:2	61:23 64:10,15	24:16 26:14	enacted 22:16	exemption 9:3
64:16	65:9,11,14 66:9	38:9,9 39:25,25	66:17	56:20,25 58:10
discussed 8:7,9	66:11,23 67:4	40:4,15,25	encourage 63:21	exemptions
66:24	67:23	43:15,15,19,20	63:22	21:13 34:8,14
dispensing 18:13	doctor's 3:22 6:4	47:20 56:5	ended 33:6	34:14 40:9
disposition 22:17	14:24 17:14	61:19 67:24	ends 8:9	expectation 37:6
dispute 56:15	48:2 49:4 68:3	Drugstores 52:9	Energy 51:3	expected 65:5
disseminate 6:19	doctor-patient	Dun 29:6	engage 47:5	expensive 28:19
dissemination	4:6	D.C 1:9,19,22	engaged 49:12	39:24 40:4
10:24 29:18	doctrine 29:4		England 10:2,21	experts 41:24
62:16	documents 57:12	<u> </u>	enormous 65:10	44:21
dissent 43:14	doing 16:8 18:2	E 2:1 3:1,1	ensure 38:7	explain 21:8 36:6
dissented 43:13	33:7 36:22 39:9	earlier11:2	ensuring 38:10	46:21
distinguish47:3	42:3 46:19	54:14 55:10	enter 46:18	explained 36:22
distort 33:3	49:10,11 54:5	66:21 67:11	entered 46:13	36:24 62:10
48:22	54:18 62:6	easier 12:7 54:7	entirely 37:14	exploitation
distributed 26:16	65:25	easily 39:23	67:16	23:25
distribution	door 12:1 30:11	easy 38:14	entities 33:23	expose 38:24
22:15	31:1 55:10	economy 61:5	entitled 17:24	expressive 32:10
doctor 6:2 7:9	double 47:19	edit 35:2	entity 8:23	extent 8:17 10:6
11:19,24 14:18	Dr 8:7 48:11	education 8:19	equal 22:19	24:2 27:22
14:22 18:9,12	drafting 59:19	66:7,9	31:12,15	44:15
18:13,18 26:15	draw 63:24	EDWIN 1:18 2:6	Erhari 8:8	extremely 50:12
26:18 35:24	drawn 10:6 22:24	22:1	ESQ 1:16,18,22	F
40:16,18,18,20	draws 50:15	effect 16:7	2:3,6,10,13	
40:24 44:25	driver's 23:21,23	effective 5:18	ET 1:4,7	fact 13:20 37:22
48:1,10 49:5,20	drug 3:19 4:1,15	16:17,20 17:6,8	evade 61:20	51:17 62:12
52:13,15 54:1	7:13,25 8:1	17:23 18:2	evading 43:17	64:14 66:24
56:23 68:4,5	12:8 14:19	29:22	evidence 66:7	facts 19:4 20:8
doctors 3:12,15	15:25 18:12	efficient 29:16	evidence-based	43:5
4:11,15,17 5:4	20:16 23:2,11	29:17	8:19	factual 11:10,13
5:23,23 6:22,25	23:12,13,13,14	effort 8:15	exactly 13:21	fall 66:22
8:4,10 12:3,24	23:15 24:7 25:8	either 19:22	43:3 61:9	falls 29:5
12:24 13:7,17	26:2,10 27:4,8	25:12 49:2	example 19:10	false 40:21,22
13:22,25 14:15	35:17 38:12	62:21	23:21 26:21,24	41:1,6,24,25
15:3,11,13,25	39:23 40:3,16	eliminated 50:21	44:1 50:19	42:9,15,24 43:2
		embrace 24:10		43:9 45:6

far 15:16 58:1	flaw 59:19	G 3:1	go 18:10 23:13	23:7 33:16
fascinating 10:1	flow 12:16 15:2	gas 51:5,8	25:7,24 34:16	34:17 37:18
10:20	focus 50:15 67:8	gather 15:7	36:2 37:2 45:15	38:2 42:23
favor 57:19	focused 29:22	gathered 31:10	47:13 56:25	48:21 51:17,20
favorite 36:13	34:9	52:11	goal 28:21 36:4	51:22 53:11,12
FBI 12:19	focuses 40:19	gender 4:18	37:2 58:8	54:8 59:21 61:1
FDA 43:16,17,21	FOIA 12:18	general 1:4,16	goals 36:10,11	62:14 63:5,6,7
44:21 45:14	following 40:14	1:18 3:5 9:16	36:15 38:5	63:16,19
59:10 61:19,20	40:24 48:4	9:16 29:3,18	goes 6:6 47:3,18	governmental
67:23	footing 22:19	30:13 34:3,13	57:15	33:2 47:2 54:10
Federal 3:12	31:13,15	34:18 36:24	going 15:23 21:9	government's
23:11 40:12,23	forbid 41:4	37:23 59:4	21:9,10 28:9,13	61:18 62:10
41:2,23 50:1	forbids 42:2	General's 18:22	31:17 33:4,5	63:12
51:2,3	form 12:22 13:23	generic 14:6 17:2	34:22,24 35:7	Granday 8:7
feel 11:17	13:24	31:23	36:22 39:5 40:1	great 37:15
feeling 12:25	former 8:8	generics 14:11	42:1,4,10 43:24	greater 50:14,16
figure 33:6	formularies 27:3	15:8 16:6	44:7,8,16 45:19	54:8 55:23
file 62:15	57:6	genuinely 48:17	46:25 47:1	Grosjean 61:25
files 3:23	formulary 56:20	61:7	52:13 53:9 56:2	ground 19:4 20:9
fill 54:17 68:10	forth 9:17 21:14	germane 28:15	56:3,18 63:2,16	58:1
filling 37:9	forward 21:9,10	getting 35:24	Goldstein 1:22	groups 12:24
filter 8:10	found 40:14	45:20	2:10 32:13,14	guy 39:4
finance 63:5	four 48:12	Ginsburg 6:9	32:16 33:24	
find 27:6 39:23	fourth 65:23	10:10 11:1 14:3	34:6.35:7 38:19	<u> </u>
40:16,22 48:2	frame 20:6	31:19 33:22	38:22 39:2,7,10	H 1:3
65:15 68:3	framed 20:20	49:22,24 50:4	39:14 41:7,11	half 33:8 38:6
finding 36:4,6,10	frankly 26:23	Ginsburg's 33:12	41:19,22 42:4	hand 33:1 53:20
37:1 38:13,14	free 15:14	53:17	42:11,14,18,22	hands 32:25
49:18 65:24	frequently 62:14	give 12:12 17:18	43:3,7,10,25	35:24 51:16
findings 32:20,21	friend 56:2 64:7	17:18 26:17,18	44:3,10,13,19	53:7,15 61:23
41:4 54:5 66:3	64:14 65:23	36:18 49:15,19	45:21 46:21	handwriting
66:16,18	68:2	49:25 50:13,18	49:8,13,23 50:4	52:15
finds 40:14	full 15:5	51:5 52:17	51:9,11,15 52:2	happen 10:12
fine 47:11 51:13	fully 19:20	53:18 58:3	52:6,20,25 53:4	40:1 51:7
63:23	fundamentally	60:19 61:25	53:7 54:21 55:7	happened 10:17
fire 51:5,6	47:24	63:3,6,14,15	55:16,20 58:15	happening 39:13
first 3:4,20 6:17	furnish23:1,15	63:17,20 65:22	58:18,21,24	59:24
21:12 29:12	23:16,23 27:18	given 11:16 13:9	59:17 60:2,7,11	happens 48:23
33:8 34:22 41:8	furnished 23:17	24:3 30:20	60:18,23 61:16	50:7
44:20 45:7 47:9	29:12	52:22	62:18,22,25	happier11:17
52:12 53:25	further 10:24	gives 50:16	good 32:17	harassed 12:23
56:10,17 63:1,3	17:16 18:19	giving 6:11 46:6	goods 31:24	12:25
66:3	57:8 65:8	46:8 48:16	govern 9:19	hard 35:21
five 64:3		49:11 50:6,7	government 3:14	harder 38:12
	G	7 -		40:1 45:19 54:6
	l	ļ	l	ļ

 (2) 7 	54 4 10 55 0	4659471	(2 (7 19 2)	57.0.50.4
62:7	54:4,12 55:3	46:5,8 47:1	63:6,7,18,21	57:8 58:4
harmful 40:21	60:12	58:14	64:8,10,15,19	intermediaries
41:1		influential 42:23	64:21,24 65:3,3	33:17 45:3
health 1:7 3:6	ideas 33:3 36:14	inform 5:16	65:6,8,13,17	internally 6:24
9:13 10:25	36:16 45:8	16:14	66:12,13 67:5,6	Internet 45:23
14:13 15:1 16:5		information 3:16	67:14,22,23	48:1,15 63:17
26:22 32:19	57:24 59:8 66:1	3:20 4:4,13,18	68:6,7,12	interpose 6:2
33:17 34:17	identifies 16:24	5:7,15,17,21	inhibitor 48:13	interpret 21:9,11
36:5,8,9 37:3,4	identity 37:7	6:12,13,19,22	ink 62:3	interpretation
38:7,16 50:11	Imagine 48:4	6:23 7:14,19	inquiry 67:9	18:22 21:2
64:24	imbalance 65:25	8:5,6,10,14 9:4	inside 4:12 26:11	interpreted
hear 3:3 15:4	impediment 5:10	9:9,20 11:25	instantaneously	19:15
heard 14:11	5:12	12:16,19 13:4	45:25	interpreting
heavily 59:6,10	implication 33:25	14:15,17,20	instruments 62:2	19:16
helpful 9:15 18:6	importance	15:2,5,11,12	insurance 6:10	intervened 15:12
36:1 65:16	47:15,23	16:13,16,20,25	26:24 38:13	introduces 56:13
helpfully 38:5	important 14:13	17:5,8,10,14	45:17 54:7 56:4	intrusive 11:20
Hey 37:14	19:23 20:25	18:6,11,16,20	56:21,22,24	invasive 11:20
highlighted	22:6 29:2,22	19:12 22:8,10	57:3 64:8,25	involved47:15
65:23	33:20 34:21	22:18,21,23	insurer 26:25	involves 54:9
highlights 65:2	40:15 61:20,21	23:1,16,17,23	28:9	irrelevant 40:19
highly 4:4 14:17	62:4 63:8	23:25 24:11	insurers 6:22,25	40:21,25
41:20	imposed 35:13	25:17 26:3,10	27:2 38:1 40:3	IRS 63:2
hinging 55:14	58:20	26:11,13,14,16	57:11 59:21	issue 18:7 19:3
HIPAA 22:11	imposes 20:15	26:22,23 27:6	64:8,10,15,19	20:6,8 33:10
26:21 32:24	35:15	27:12,12,17,23	intend 13:11	issuing 27:19
37:23 57:19	IMS 1:7 3:6	28:4,11,16,17	intended 6:21	item 23:15
64:20 65:2	32:19 33:17	28:25 29:12	15:17 48:24	
history 52:10	36:2 56:9	30:1,1,5,8 31:9	50:16 63:24	J
hold 15:19,20	inaccurate 20:17	31:17 32:7,25	65:5	Journal 10:3,21
homeowners	incapable 13:16	33:2 35:2,4,11	intercede 46:6	journalist 38:24
51:8	include 34:4	35:23 37:6,15	interest 12:2,15	judgment 17:21
Honor 4:10 5:22	included 67:21	38:10,21 40:8	12:19 14:12	17:24
6:16 7:8 8:3,16	including 9:20	40:10 44:16	16:5 28:7,7	judgments 37:17
9:12,18 11:9	37:7 66:6	47:11,16,17	29:10 38:16	jump 34:12
12:13 13:20	inconsistent 19:8	48:15,16,22	46:11 47:25	Justice 1:19 3:3
15:9,24 16:18	Incorporated 3:6	49:4,6 50:8,12	53:25 55:23,25	3:10 4:7,20,23
18:4,24 19:19	32:19	51:4,19,19,22	59:21,22 61:1	5:1,1,6,9,19 6:1
20:4,19 21:5,11	increase 11:14	52:6,11,17,18	interested 14:5	6:9 7:3,11,22
66:2 68:15	47:21 57:10	53:16 54:16,23	16:1 27:13	8:12,20 9:7,14
hour 33:8	incredibly 59:11	55:19 56:12	41:13,15	9:24 10:10,11
hypothetical	indicated 27:10	57:4,10,15	interests 13:6	10:15,18 11:1,3
10:12 11:12	individual 31:10	59:11 61:23	22:7 30:13	11:7,14,22 12:4
44:4 53:6,14,19	individuals 45:24	62:10,13,15	38:18 50:25	12:21 13:9 14:3
ттт JJ.0,14,17	industry 41:21	02.10,13,13	50.10 50.25	14:25 15:15

160 7 10 16	0.04.10.11.15	CO O		
16:3,7,10,16	9:24 10:11,15	60:9	limitations 49:7	64:7 67:11
16:19,23 17:17	10:18 11:4 16:3	knows 7:5 28:8	limited 4:25 29:7	malpractice
18:21,25 19:7	19:7,13 29:14	Kolassa 57:3	29:10 30:6 31:6	37:17
19:13,23 20:12	29:21 35:6	L	49:12	manage 64:21
20:22 21:6,8,23	52:16,21 53:2,5		line 50:15,16	mandated 66:12
22:4 23:5 24:1	54:14 60:16	laid 19:20	lines 63:24	manufacturers
24:6,13,19,23	61:9	language 35:14	link 36:7	4:22 8:1 15:13
25:4,22 26:2,6	Kennedy's 11:7	55:9	list 27:8 31:23	15:17 16:13,22
26:15 27:9,20	60:12 66:21	LAPD 51:11,16	32:7,8	18:5 21:18 51:8
28:3,10,16	kept 25:18	52:24,25 53:1,3	listener 14:1	64:9,23 68:5
29:14,21 30:7	Kerry-McCain	53:12,13,14	67:25	manufacturing
30:10,18,22	55:22	63:3,8	lists 27:4	40:13
31:2,19 32:3,12	Kesselheim 8:8	larger 66:5	litigating 20:10	market 5:3,21
32:16 33:12,22	key 51:15	Laughter 41:16	little 49:20 57:14	7:15 25:19 59:7
34:3,9,12 35:6	kind 14:15 40:7	52:5 55:6 60:17	lives 37:13	marketer7:24
35:15,20 38:15	54:23	law3:12,15,25	locate 15:25	7:24
38:20,23 39:3,8	kinds 37:18	5:25 17:12	long 23:18 24:13	marketers 8:1
39:11,17 40:11	Kneedler 1:18	22:11 23:11	35:3,10	marketing 3:17
41:9,13,17,20	2:6 21:25 22:1	24:20,24 25:5	longest 46:1	3:20 4:1,19
41:23 42:7,12	22:4 23:10 24:5	25:15 26:17	look 32:21 39:23	5:11,16,17 6:7
42:16,19,24	24:9,18,21,25	30:18,24 48:6	48:5,25 50:18	6:21 7:20 11:20
43:1,5,8,12,24	25:10 26:1,4,7	50:1 68:9	50:20,25 53:16	14:1,16 17:11
44:1,5,11,14	26:19 27:15	lawyer 36:23	55:1 56:4 61:15	18:7,17 19:12
45:21 48:18	28:1,5,14,20	lawyers 35:25	61:16	20:16 21:16
49:1,9,22,24	29:20,24 30:8	learned 14:22	looking 16:23	22:23 23:3
50:4,5 51:2,10	30:15,21,23	leave 14:21 47:1	lose 55:4	33:19 34:2
51:13,18 52:16	31:4,19 32:1,4	leaves 22:11	lot 7:7 24:3 38:25	35:17 36:8,11
52:21 53:2,5,16	59:4 62:10	legislative 12:23	39:25 60:5	36:25 37:1,12
54:13,14 55:13	knew 13:14	65:24	lots 58:19	37:25 40:19
55:17 58:13,16	48:14	legislature 12:14	love 37:12,16	59:6 61:19
58:19,22 59:13	knock 30:25	22:7 35:25	lower 14:9,25	65:18 66:14
59:25 60:3,8,11	knocking 30:11	42:20 44:18 65:14 67:1	15:1 55:24	67:7
60:15,16,20,21	know 7:5,7,9,24		Lukumi 61:15	marketplace
61:8,9 62:9,19	11:10 15:22	legitimately 32:6 46:12	<u> </u>	33:3 36:14,16
62:23 64:2	17:1,2 23:8	lesser 25:11	magazine 13:18	45:8 57:23 59:8
65:21 66:15,20	24:14,16 26:25		mail 30:3	66:1
68:8,16	32:24 33:1 41:7	lesson 55:4,5,8 63:8		matter 1:12
K	41:7,8,18 44:14		mailing 13:17	11:10,13 30:14
Kagan 21:8 34:3	48:11,20,21	let's 5:14 30:10 34:20 35:21	main 63:25 maintain 25:3	32:23 40:18
34:13 60:21	51:23 53:3 56:7	level 14:10	maintained	44:17 68:19
Katie 55:10	60:4 62:16	license 23:24	31:21	McCain-Kerry
keep 31:17 58:12	68:11	lifesaving 47:18	majority 13:16	46:24 57:20
keeping 61:22	knowledge 7:14	lifespan 47:21	majority 15:16 making 15:16	mean 5:13 17:24
Keeping 01.22 Kennedy 9:7,14	known 37:17	limit 15:10 35:23	17:4,21 62:7	23:7 24:2,15
Iscinicuy <i>7.1</i> ,14		mint 15.10 55.25	17.7,21 02.7	

Г

25.22 28.6 20		29.12 26.4 6 10	and marry 64.11	27.9 40.2 15 25
25:22 28:6,20	monitor 4:15	28:12 36:4,6,10	ordinary 64:11	37:8 49:3,15,25
28:21 34:10	monitored 65:18	36:13 37:2	Orleans 54:9	49:25 50:2
39:19 43:2	Montpelier 1:17	0	outrage 61:4	64:19,20
49:20 50:2 67:1	morning 3:4,4	$\frac{0}{02:13:1}$	outraged 48:9,13	patients 3:13
meaning 13:11	32:17		48:17	4:14 6:25 8:6
19:24	motive 62:4	object 65:19	outside 39:6	12:3 37:5 49:3
means 17:25	N	objected 16:15	49:11	49:14 50:7
20:3 43:2		objection 59:14	overall 26:11	64:13 65:12,17
mechanism	N 2:1,1 3:1	59:18	owned 53:13	patient's 14:23
14:14	name 14:7 23:16	objectionable	O'Brien 66:23	28:8 57:8
medical 27:1	24:2 31:22,23	65:16		pay 6:14 39:25
37:16 48:16	46:1,14 52:14	objective 7:23	P P	56:23
medication 14:21	narrowly 22:24	25:21	P 3:1	payers 57:11
39:1	28:24 31:7	obtained21:18	page 2:2 9:21	paying 6:12
medications	57:25	obvious 5:12	19:10,12 20:13	26:24 56:5
47:18	National 52:9	obviously 36:13	34:24 35:6,8,9	64:12
medicine 10:3,22	natural 51:5	44:7	36:3,23 37:4	payment 37:9
28:8 36:14	nature 47:25	office 48:2 68:3	38:3 49:19 53:9	pejorative 15:3
members 63:9	59:8	Oh 39:14 41:9	56:10,10 57:12	pending 46:23
63:10	nearly 61:1	62:25	64:18	people 7:7,9,15
message 38:1	necessarily 5:13	okay 35:12 36:3	pages 20:5 52:10	11:6 24:16 27:4
45:13 47:13	12:2 27:5	43:25 60:20	paid 6:11	30:4,11 39:5,5
55:12 57:17	necessary 16:16	62:25 63:2	paragraph 38:6	41:12 48:11
58:11 59:20	16:20	ones 17:23 18:2	56:11,17,18,19	49:11 50:21
67:21	need 7:1 15:19	one-on-one 29:8	56:21	60:4 63:21,22
messages 43:20	21:19 59:5	29:9,11	parallel 56:20	65:7
44:20	needs 23:8 26:25	one-sided 43:2	parents 64:11	percent 47:21
method 13:1	Network 50:19	operating 36:15	part 46:5,12 48:3	perfectly 13:24
middle 33:5,6	never 55:4 67:20	opportunity 67:5	55:20 64:12	59:11 61:21
48:19 57:21	67:21	opposed 40:7	65:12 66:13	62:5 63:23
million 46:4,8	new 7:25 10:2,21	opposite 38:1	particular 4:9	permissible
mind 34:20 46:17	40:25 54:8	43:19 45:16	29:19 38:25,25	21:18 28:15
miners 6:12 11:5	news 50:21,23	opt 13:18 46:9	68:10,11	65:6
Minneapolis	50:24	47:6 49:3	particularly 8:4	permit 8:13,13
62:1	newspapers 9:17	option 26:18	27:13	8:21,24 9:1,13
minute 34:8	61:5	36:20 46:7	parties 32:25	15:19,20
minutes 21:24	newsprint 62:3	options 50:7	parts 21:21	permits 67:23
52:13 64:3	nine 63:9,10	opt-in 13:2 46:17	party 27:13	permitted 40:5
misleading 33:15	nonprescription	opt-out 13:2,2,4	passed 61:11,12	permitting 49:2
41:6 42:9,15	14:19 23:14	13:5,13 36:20	paternalistic	person 23:13,22
45:6	nonpublic 67:6	46:7,17	58:7,9	29:11,25 35:3
misunderstand	67:16	oral 1:12 2:2,5,9	patient 3:23 6:23	35:11 48:9 59:4
21:1	NPI 56:14	3:8 22:1 32:14	7:10 9:22 14:19	personal 26:22
money 45:11	number 10:1	order 5:3 7:15	14:23 17:8	persons 26:22
· ·	13:19 23:20	23:23 27:6 33:5	18:12 22:9,10	-
	l	l	l	

persuade 39:24	physician 7:4,12	34:7,22 35:22	24:16 27:7 60:4	primarily 6:21
petition 20:13	7:12,17,19 12:7	39:16,17 43:12	62:13 68:4	primary 22:12
21:3 30:12,19	22:8,12,19,24	50:8 51:15	prescriber 6:11	principal 55:20
39:20	22:25 23:4	52:12 64:7,16	22:19,22,23	principle 63:25
Petitioners 1:5	25:13,15,19,20	65:22 66:21	27:5,16,17,18	principles 25:1
1:17,21 2:4,8	26:9 27:16,22	67:11	45:4 64:21	prior 22:16 30:20
2:14 3:9 22:3	27:24 28:3,8,23	points 64:18	prescribers	40:24
64:5	29:12 31:12,14	policing 46:5	38:10	privacy 11:15,18
pharmaceutical	32:6 50:3 60:1	position 17:12	prescriber's	12:6,10,11,14
4:22 12:1 15:13	60:4 68:9	19:1,3,21,24	24:15	12:18,22 13:6
16:13,22 18:5	physicians 4:9	20:24,24 25:13	prescribes 7:4,6	23:21,22 24:2,4
21:17 25:12	26:8 38:24	27:5 50:10	7:9,12 14:19	24:10,15 25:5,6
29:15 31:8,16	39:12 57:5,12	possession 32:5	prescribing 4:13	25:23 27:22
33:19 36:8	57:13	post 30:15	6:22 7:5,16,18	30:13 37:23
37:11 40:13	physician's	posts 30:24	7:19 11:15,16	38:17 39:12
64:9,22 66:12	11:15 28:25	Power 51:2	15:6 17:14	40:7 45:24
68:4	31:9 38:17	practice 11:21	18:12 23:2	47:25 48:25
pharmacies 3:17	physician-iden	33:9 40:22 41:6	26:11 48:3 57:7	53:21,25 55:2
6:18,19 7:1	57:4	42:1,9 48:3	57:13 67:7	55:24 58:3 60:1
11:11 19:5 25:3	PI 56:24	60:6 65:16	prescription 4:5	60:24 61:2,7
49:2,6 54:18	pick 59:24	practices 6:23	20:7,16 22:9	private 7:4 32:25
67:19	picked 39:22	7:20 17:14	23:8,11,12,12	37:14 38:7
pharmacist 6:11	58:9,10	26:12 33:9	23:13,18 27:19	40:10 48:8,16
31:21,22	Pickett 39:6	40:13,20,24	35:17 37:7,10	50:11 53:20
pharmacists 6:13	picking 62:7	45:4 67:7	38:8 50:8 52:14	54:9 63:12,19
6:15 11:5	piece 23:19 59:9	practicing 28:8	52:21 54:17	65:3 67:17,18
pharmacist's	59:10	practitioner9:22	62:12 67:24	problem 31:6
31:24	pieces 62:25	preapproved	68:10	39:21
pharmacy 6:7 9:5	pitch 45:15,16	43:21	prescriptions	problematic
9:20 10:13,15	47:17	precedent 42:8	3:13 24:3 26:25	27:10
10:24 14:20	pitches 4:1	precedents	37:5	process 66:14
18:13,13,15,18	place 6:18 18:18	27:10	present 41:14	processing 37:9
22:10,13,17,20	48:6 65:10	preempt 56:1	presentation	product 17:1
22:20 23:8 25:2	68:11	58:5	25:21 26:13	46:3 57:14
25:18 29:13	places 9:21	prefer 26:12	press 62:7	products 4:2,3
31:13,15 32:5	placing 5:11	37:18 39:25	pressed 19:3,19	16:1 23:3
33:14 49:5	play 16:15	preferred 27:4,7	presumably	professional
52:17,19 53:10	player28:23	preparer 63:14	62:19	13:18
53:12 54:17	please 3:11	preparers 63:20	prevent 4:8 5:20	professionals
59:2,2 60:19,21	20:22,23 22:5	prepares 62:20	10:24 30:13	22:13 37:3,4
68:11,12	32:17	prescribe 4:17	39:12 41:5	profile 9:15
PhRMA 35:8	plenary 63:5	15:8 38:25	59:24	program 8:18,19
64:18	point 18:15 20:5	48:12	prevents 39:9	40:2,3 56:17
PhRMA's 34:24	20:25 22:10	prescribed 14:22	previous 40:20	59:16 61:21
		1		

66:7,8	67:14	16:7 18:21 32:2	57:1 59:19	regime 4:4
programs 36:11	provisions 21:14	33:12,20 34:12	63:18 67:4	regulate 3:25
56:16	public 9:16,16	35:19 41:10	reason 32:21	42:9
prohibit 29:17,23	13:17 29:5,10	48:23 50:2,5,13	48:18 51:21	regulated 4:4
prohibition 34:13	37:19 39:3	53:9 54:15 61:7	53:24 54:22	14:18 41:20
34:16,19	46:13 47:14,22	67:4	58:9,10 63:14	58:14 59:7
prohibits 23:24	47:23 55:23	questioning 33:8	63:15,16	regulates 4:3
projects 4:19	67:15	questions 17:16	reasonable 37:6	59:10
promote 44:15	publicity 40:8	17:18 65:1	48:9	regulating 16:8
promoting 14:6	publicly 67:20	quibble 5:14	reasonably	32:9
20:16 35:17	pull 52:7	quick 43:13	50:12	regulation 15:2
promotion 38:9	pump 48:12	quite 12:10 23:6	reasons 10:2	22:14 23:7
protect 12:5 13:5	purchase 23:14	34:1 50:10	15:10	regulations 9:19
23:21,21 24:1,4	purchasers 38:8	quote 35:1 57:3,9	rebuttal 2:12	23:20 25:2
24:6,7 25:1,5	purchasing 7:2	quoted 35:15	17:19 21:24	58:20
25:23,24 27:22	purpose 4:7,8,11	55:9	56:3 64:4	regulatory 43:17
30:12 32:24	5:2,4,12,14,19	quotes 56:17	receive 8:11,11	51:3 61:20
46:20 48:24	5:20,22 6:21	quoting 35:14	13:24 15:11	rehearing 21:4
58:2	9:1,11 12:5,7,9		64:10 65:13	reiterates 38:5
protected 12:11	14:4,8 28:18	<u> </u>	received 7:10	rejected 59:1
22:11 24:19,23	29:19 31:1	R 3:1	38:10	relates 12:22
50:2 61:7	35:23 51:23	racks 50:21,23	recognize 22:7	relating 13:13
protecting 12:10	61:12,13,22	50:24	29:2 32:6	relationship 4:6
39:12 40:6	62:6 64:19	radio 29:8	recognized 12:17	relationships
46:12	65:18	Raglan 62:1	record 4:14 6:18	6:24
protection 23:22	purposes 4:21,25	raise 62:5 65:1	8:3 12:24 31:21	relicense 13:22
30:17 46:24	6:8,10,10 9:8	random 47:16	31:23,24 53:14	rely 18:1 35:25
50:11	19:6 21:19	rap 12:19	64:17 66:25	remain 52:18
protects 22:6	27:23,25 28:12	rationale 61:21	67:2	Remember
25:5,6 26:21	28:17,18 34:2	62:5	records 3:24	39:16 49:14
60:24,24	37:8 41:14	reach 15:17 54:6	20:7 37:18	61:17
protest 63:21	51:24,25 56:12	54:8	red 32:19 35:8	remind 60:15
proton 48:12	push 59:15,20	read 34:23 49:1	redefine 50:25	reply 56:13
provide 3:17 4:2	put 18:17 22:18	49:9,18 50:6	reduce 14:7	Reporters 12:17
15:13 23:6,6	25:12 27:13	52:15	reducing 14:13	Reporting 51:12
57:14 64:25	28:22 52:13	reading 34:24	16:5	51:16
66:8,13	62:15	real 53:21 55:2	reexamined	reports 63:5,12
provided 27:1	puts 25:21 31:12	59:21,22	58:23	63:12
57:11 67:22,24	31:12,14	really 8:20 9:9	refer 12:14	representation
providing 64:12	puzzle 63:1	13:11,16 16:20	reference 34:23	19:16,17 29:25
provision 9:2		19:19 20:10,20	52:10	representative
21:15,16,20	<u>Q</u>	23:19 29:7	reflect 51:1	8:9
34:4 37:23	quality 17:2	35:20 43:13	refusing 7:23	representatives
40:10 66:6,11	question 8:21,21	46:14 47:13	regarded 50:12	4:8,12
	9:4 10:5 11:1,7	48:22 55:13,14		
	1	1	1	1

representing	16:11,12 21:12	28:3,10,16 30:7	40:10 41:9 42:8	61:5 62:21
19:14	21:15,17,20	30:10 32:3,12	43:14 45:19	68:12
reproduces	33:2 66:22	38:15,20,23	46:13,25 47:4	selling 16:6
32:20	67:22,25	39:3,8,11 59:13	47:10 51:22	31:22 40:24
require 6:3 23:11	restrictions 9:22	59:25 60:3,8,15	53:17 54:11	48:15 58:16,20
25:2	13:10 20:15	60:20 62:9,19	55:10 56:23	sells 10:15
required 10:23	35:16 52:23	62:23 64:2	63:20	send 57:11
23:1,5,6,22	67:13	65:21 66:15	Scalia 4:20,23	sense 7:4 25:6,6
27:18	restrictive 13:1,4	68:8,16	5:1,6,9,19 6:1	25:23
requirement 6:2	25:11	rolled 57:12	7:3,11,22 11:14	sentence 19:10
6:6 23:17	restricts 16:19	rule 9:20 33:11	11:22 12:4	separate 9:1
requirements	62:17	41:2,8 45:1,18	16:16,19,23	serious 40:6 65:1
43:17	result 8:3 10:22	46:22 59:2	19:23 24:1,6,13	serve 29:18
requires 12:25	resulted 66:19	60:18 61:10	24:19,23 25:4	services 27:1
51:20 62:13	results 10:5,20	63:20	25:22 26:2,6	set 21:13 47:1
research 9:8,10	return 62:15,20	rules 9:5 25:18	30:18,22 31:2	SG 19:15,21
9:13 10:7,25	66:20 67:10	47:2	35:20 43:1,5,8	sheet 12:20
34:16,18	returns 3:22	ruling 53:5	scientific 47:19	show 64:18
researcher9:14	revenue 62:5	run 14:8	57:11	shows 4:14 6:18
9:25,25 10:2,16	review40:3	runs 54:2	second 20:5,17	8:3
10:18,19,20	44:21		20:25 21:15	shut 11:24
researchers	right 3:21,21 4:9	S	33:20 34:11	side 43:6,22
11:11 26:17	4:21,23 5:2,6,9	S 1:18 2:1,6 3:1	35:1,5,12 38:6	45:19 59:9,22
33:14,16	6:4 7:7,17	22:1	39:18 44:23	sides 17:3 45:9
respect 6:17	10:17 11:15	safety 36:14	47:14 48:7 54:2	59:24
22:20,21,22	15:8,18,19	sale 3:15 6:7,8	56:19 63:2	sign 30:12,15,25
27:2 29:11 32:8	16:17 17:13,25	6:20 9:1 10:7,8	secrets 17:9	signers 30:19
66:16	18:8,8 20:7	11:4 14:6,7	63:16	significant 54:1
respecting 49:7	23:7 24:13,17	19:5,11 20:15	section 40:23	similarly 64:9
respond 44:6	25:9 26:6 28:1	21:13,13 33:19	48:7 61:2	simply 7:23
65:22	29:19 30:4 34:8	34:4,13,15,18	sections 66:6	49:10 67:1
Respondents	36:3 37:20	35:16	sector 38:8	situated 64:9
1:23 2:11 8:12	38:21 39:9 40:7	sales 4:8,12 8:8	see 25:20 26:8	situation 25:14
8:17 32:15	40:11 41:19	33:13,23 34:2,4	42:10 46:11	30:2
responsible	43:3,7 45:9	salesman 25:8	51:19	slamming 12:1
47:20	46:9 47:6,7	saying 11:22	seemingly 63:9	Smith 48:11
restatement 48:7	50:10 51:13	12:11 15:21	sell 9:16 10:2,21	sold 9:7,10,13,24
61:3	52:3,8 53:4,14	16:17 27:22	11:2,5,6,7,11	10:13 11:17
restrict 14:1 68:7	58:7,21 62:18	29:16 30:12,16	12:8,11 20:7	18:16 40:15
restricting 15:2	62:22 65:11,19	30:25 31:16	33:14,15,16,16	49:5
15:15 17:5	ROBERTS 3:3	41:14,15 54:13	35:2 38:20,23	solicitations
19:11 43:9,11	4:7 14:25 15:15	54:15,19,21,22	46:1,9,14 49:6	13:14 30:16
45:12	17:17 21:23	54:25 58:2,22 says 7:24,25 9:9	50:22 51:8	Solicitor 1:18
restriction 10:8	23:5 27:9,20	20:14 30:6 36:3	52:18 60:22	18:22 36:23
		20.14 30.0 30.3		
L				

59:3	starts 51:19	35:13,13,15,18	subsidy 53:17	25:4 34:5 45:4
somebody 30:19	56:19 67:17	38:3 39:15,16	suggested 5:2	46:25 49:16
somewhat 33:15	state 3:12 13:12	39:18,19 47:9	8:17 68:2	65:9
Sorrell 1:3 3:5	13:21 14:5,12	47:10,10 48:23	suggestion 58:6	talks 47:19 56:21
sorry 28:11 35:7	15:11 16:5	48:24 49:10,24	suitably 27:7	target 4:19 37:24
59:8	22:11,25 23:11	50:9 51:1 52:1	suits 58:4	targeted 29:7
sort 6:16 24:10	27:11 28:13,19	52:16,23 53:21	summarizing	targeting 18:7
26:11 29:17	28:22 29:16,23	55:2,9,9 56:25	20:13	50:23
30:17 61:5	30:18,23 32:5,8	57:25 60:10,13	support 66:4	tax 3:22 62:2,3
Sotomayor 12:21	33:13,24 34:25	61:11,12,13	supporting 1:21	62:15,20 63:14
13:9 45:21	35:12,22,25	63:10,13 65:1	2:8 22:3	63:20,20
48:18 49:1,9	36:3,12,14,16	66:5,9,16,19	suppose 40:11	taxes 63:22,23
50:5 54:13	36:18,21 37:3	66:21,24 67:2	40:12 44:14	taxing 62:2
55:13,17 61:8	37:22,22,24	67:12 68:7	52:16	telephone 13:13
sought 38:6	38:5,6,8,14	statutes 26:21	supposed 45:10	television 29:8
source 18:10	40:2 43:5,22	32:20,21,24	Supreme 1:1,13	tell 12:5 13:11
speak 17:4 62:8	46:6,12,16,18	48:20 49:10	sure 10:4,12 15:4	15:7 45:9 63:17
speaker 14:2,10	49:15 52:22,22	61:11 65:4	39:7 42:14	telling 13:17
14:10 47:12	53:15 54:15,16	statute's 56:19	44:13,19 49:13	tells 60:5
50:17 54:24	56:2,13,16,19	stock 31:24	51:9 53:7,8	term 24:9
57:2 64:15 68:1	58:8,9 59:15,19	stop 5:2 44:8	56:7 58:18,21	terms 18:19
speakers 54:11	59:23 65:25	49:22 54:16	60:7,7,18	Terrific 45:16
58:11 63:25	States 1:1,13,20	59:5	surprisingly	testifying 12:24
speaking 18:3	2:7 22:2 41:3	store 23:14,15	41:15	Thank 21:22
specialists 41:24	42:2 43:14 59:5	story 45:9	surrebuttal 56:8	32:12 64:1,2
specific 54:23	61:17	stove 51:7	switch 4:16	66:2 68:16
speech 13:10	State's 25:2	stoves 51:8	system 22:15	thankfully 58:24
16:8,11,17,20	35:25 36:23	straight-out 57:2	26:23 28:24	59:20
17:6,7,22 18:2	38:16 53:16	stream 18:16		thing 7:11 13:10
29:4,17 31:20	56:11 58:8	31:14		27:2 36:18
42:23 43:22	statute 4:11,24	striking 66:24	T 2:1,1	39:22 45:9
45:12 47:15	6:6 8:13,21,24	strong 36:7	tailored 13:25	50:14 61:6,6
48:22 54:10,10	8:25 9:2,12	structure 47:9	28:24 31:7	63:4
55:24	10:6,22,23 12:9	48:24	take 14:20 15:7	things 17:3 28:19
spending 36:9	13:8 14:14	structured 65:4	34:15 36:21	33:8 40:17
sphere 37:19	15:10 18:17,23	studies 47:19	43:1 50:18 55:3	44:19 46:15
spread 45:25	19:11,15,25	study 40:13	55:5 56:24	48:8 49:13
54:16	20:14 21:2,9,10	42:20	57:17 59:14	55:22 57:20
stake 18:14 32:7	21:12,14,15,21	stuff 37:13 50:22	60:11 68:8	think 12:13 16:3
stand 66:22	22:6,16,18,24	55:11	taken 50:1 66:3	17:23 18:3,4
standing 23:18	23:19,24 27:15	subject 22:14	talk 7:24,25 8:1	20:1,20 21:2
Star 62:1	28:10,11 30:3,4	submitted 68:17	11:23 24:8 26:5	29:5 30:16,21
start 38:4	32:11 33:10,21	68:19	31:3,4 45:1,2 61:3	30:23 31:22
started 48:18	34:7,10,21	subsection 38:4		33:7 34:1 39:12
			talking 24:14	

42:22 53:21,25	46:19,19 47:5	unbiased 38:10	10:8 24:4 27:11	9:9 11:23 12:8
54:12,14,18	48:1 49:12	44:16	27:12 28:4	13:3,7,18 14:16
57:1 60:12,25	67:18	unconstitutional	34:15 40:5 47:6	14:25 15:1,5,18
66:20,21	transmission	53:22,24 54:20	64:20 65:6,6	15:20 24:7
third 21:16 32:25	67:17	54:22 61:14,24	utilization 40:3	25:17 26:4,9,16
45:7 47:24	treated 55:18	62:8 63:13	56:16	27:24 31:3,4
THOMAS 1:22	treating 39:4	underlying 18:11		32:18 33:7
2:10 32:14	treatment 65:11	understand 10:4	V	34:10,23 38:4
Thompson 12:25	tremendous	16:9 20:18 21:5	v 1:6 3:5 43:13	38:21 44:8,24
43:13 59:5	47:22	35:13 45:22	50:19 51:11,16	45:5 46:8,14,14
61:17	trends 4:17	60:24	59:5 61:17	48:5 49:4,6
thought 27:9,20	trials 4:25 34:17	understood	valid 62:6	50:22 51:3,7,22
27:21 44:6	tribal 54:10	11:12 20:14	valuable 59:12	51:24 53:2
thousand 46:3	tried 35:20 39:17	35:18 39:19	value 26:8	55:10 56:6 58:5
threat 50:11	tries 35:22	United 1:1,13,20	variety 28:2	58:11 60:3,9
three 33:8 47:8	troubling 54:12	2:7 22:2 41:3	56:12	65:21 68:10
48:11 55:22	true 28:2 36:17	42:2 51:11,16	vast 13:15	wanted8:22,23
throw 55:25	37:1 43:5,11	universities 11:8	vendors 6:20	36:18 59:20
time 13:21 17:19	49:16 58:13	university 8:22	19:6 35:1 67:19	wants 10:21
22:16 38:13,14	63:4,4	9:8,8,10 10:19	Vermont 1:4,17	38:24 43:22
44:24 45:19	truly 60:1	unprofessional	3:5 8:22,22	Washington 1:9
46:1 48:21 56:7	trumps 18:8	59:3	22:6,7 28:13,19	1:19,22
56:10	trust 65:10	unrestricted 3:15	33:6,11 37:3,4	wasn't 8:20
times 48:12	truthful 43:17,21	upsets 45:8	39:22 40:6	watch 4:16,16
57:16	67:23	use 4:20,24 5:24	42:13 44:18	way 13:23 15:12
today 45:22 46:5	try 45:5 57:5,6	5:24 6:1,6 8:14	45:8,15 52:22	17:13 24:11
56:14	trying 11:3 38:11	12:16 15:3	52:23 54:4 56:2	26:10 31:24
told 11:4 19:8,14	38:11 54:4	16:14,15 17:11	56:2 57:22 58:1	37:2 40:17 45:7
19:25 27:20,21	57:23 58:2,3,8	18:17,19 19:12	65:14	45:13 57:7 65:5
34:25 48:11	62:5	20:15 21:16,20	Vermonters 36:9	67:20
tool 67:7	Tuesday 1:10	22:21,22 25:17	Vermont's 3:15	went 58:1
top 35:9 36:3	turn 34:11,20	27:5 28:25 30:8	3:25 8:18 13:16	weren't 37:17
torts 48:7 61:3	35:5	31:9 33:2 35:3	21:1	62:11
totally 12:6	two 6:16 15:10	35:11,16 37:24	version 25:11,11	Western 43:14
48:25	22:12 61:11	37:25 39:24	Virginia 59:1	59:5 61:17
town 15:19	62:25	40:23 47:11	virtually 13:14	we'll 17:17,17,18
track 4:15	twofold 53:25	48:21 50:22	45:23 57:15	21:23
trade 17:9 31:25	types 23:20	53:20 56:11,15	visit 25:16 29:25	we're 17:20
40:12,23 41:2	typify 46:22	61:4 62:14 64:7	44:24,25	24:12 33:5,17
41:23	U	64:12 65:8	voluntary 66:9	39:5,14 40:1
transaction		66:11 67:5	volunteers 68:6	46:25 47:1
18:11,14 19:5	unauthorized	useful 18:6	W	49:16 50:23
20:9 22:12	47:6	user 55:19	walk 14:20	58:2,3 62:3
45:24 46:13,16	unbelievably	uses 6:3 8:19	want 5:24 7:25	65:8
	57:22		,, ture 5.2 1 7.25	

we've 50:20	22a 20:13 35:14		
William 1:3 3:5	26 1:10		
willing 14:1,2	29 19:10 37:1,2		
67:25 68:1	49:19		
win 42:5,5 61:17	3		
wish 37:13			
wondered 44:5	3 2:4 36:10		
word 15:3	3-year 40:12		
work 57:24	30 19:10 52:12		
works 45:7,13	32 2:11		
world 45:25			
worried 62:4	4		
worry 17:20	4 9:21 36:13		
wouldn't 13:12	40 47:21		
40:9 55:25	42 34:24 35:8		
62:11	47 20:5		
write 3:12 37:5	48 20:5		
60:9			
written 66:5,10	5		
	5 21:23 40:23		
wrong 17:25	50 46:4		
X	53 56:10,10		
x 1:2,8	57:13		
A 1.2,0			
Y	6	`	
years 13:22 57:9	64 2:14		
Jours 19122 9119	652D 48:7 61:3		
\$			
\$20 14:21	7		
\$5 56:23	7 36:23 37:4		
·	49:19		
1	8		
1 36:4			
1a 36:3	80 47:4		
10 52:10	9		
10-779 1:5 3:5			
10:06 1:14 3:2	9 38:3		
11 52:10			
11:14 68:18			
126 64:18			
2			
2 13:22 36:6			
20 9:20			
2011 1:10			
2011 1.10 22 2:8			